Azenta (AZTA) 10-Q 8 Aug 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	9 Months Ended
	Jun. 30, 2023	Aug. 03, 2023
Cover [Abstract]
Entity Central Index Key	0000933974
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	000-25434
Entity Registrant Name	AZENTA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3040660
Entity Address, Address Line One	200 Summit Drive
Entity Address, Address Line Two	6th Floor
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	978
Local Phone Number	262-2626
Title of 12(b) Security	Common Stock, $0.01 par value
Entity Listing, Par Value Per Share	$ 0.01
Trading Symbol	AZTA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		60,153,892
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Current assets
Cash and cash equivalents	$ 733,369	$ 658,274
Short-term marketable securities	390,492	911,764
Accounts receivable, net of allowance for expected credit losses ($8,403 and $5,162, respectively)	163,019	163,758
Inventories	142,102	85,544
Derivative asset	984	124,789
Short-term restricted cash	2,287	382,596
Prepaid expenses and other current assets	78,584	132,621
Total current assets	1,510,837	2,459,346
Property, plant and equipment, net	210,940	154,470
Long-term marketable securities	169,422	352,020
Long-term deferred tax assets	599	1,169
Goodwill	793,623	513,623
Intangible assets, net	312,055	178,401
Other assets	71,940	57,093
Total assets	3,069,416	3,716,122
Current liabilities
Accounts payable	37,990	38,654
Deferred revenue	45,207	39,748
Accrued warranty and retrofit costs	6,258	2,890
Accrued compensation and benefits	33,848	41,898
Accrued income taxes payable	2,571	28,419
Accrued expenses and other current liabilities	77,753	78,937
Total current liabilities	203,627	230,546
Long-term tax reserves	1,738	1,684
Long-term deferred tax liabilities	65,700	64,555
Long-term pension liabilities	288	261
Long-term operating lease liabilities	61,799	49,227
Other long-term liabilities	12,764	6,463
Total liabilities	345,916	352,736
Stockholders' equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value - 125,000,000 shares authorized, 74,656,860 shares issued and 61,194,991 shares outstanding at June 30, 2023, 88,482,125 shares issued and 75,020,256 shares outstanding at September 30, 2022	747	885
Additional paid-in capital	1,323,215	1,992,017
Accumulated other comprehensive loss	(37,145)	(83,916)
Treasury stock, at cost - 13,461,869 shares at June 30, 2023 and September 30, 2022	(200,956)	(200,956)
Retained earnings	1,637,639	1,655,356
Total stockholders' equity	2,723,500	3,363,386
Total liabilities and stockholders' equity	$ 3,069,416	$ 3,716,122

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Allowance for expected credit losses	$ 8,403	$ 5,162
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	74,656,860	88,482,125
Common stock, shares outstanding (in shares)	61,194,991	75,020,256
Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]
Treasury stock, shares (in shares)	13,461,869	13,461,869

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
Total revenue	$ 165,948	$ 132,735	$ 492,715	$ 417,931
Cost of revenue
Total cost of revenue	97,943	73,135	297,609	220,462
Gross profit	68,005	59,600	195,106	197,469
Operating expenses
Research and development	8,968	6,515	25,024	19,895
Selling, general and administrative	75,465	58,133	241,356	186,761
Contingent consideration - fair value adjustments	(1,404)		(18,549)	600
Restructuring charges	812	25	3,773	319
Total operating expenses	83,841	64,673	251,604	207,575
Operating loss	(15,836)	(5,073)	(56,498)	(10,106)
Other income (expense)
Interest income	11,347	6,822	32,406	9,933
Interest expense		(2,101)		(4,111)
Loss on extinguishment of debt				(632)
Other, net	819	630	(704)	(1,617)
(Loss) income before income taxes	(3,670)	278	(24,796)	(6,533)
Income tax (benefit) expense	(1,207)	7,293	(9,107)	(560)
Loss from continuing operations	(2,463)	(7,015)	(15,689)	(5,973)
Income (loss) from discontinued operations, net of tax	993	(2,555)	(1,943)	2,159,597
Net (loss) income	$ (1,470)	$ (9,570)	$ (17,632)	$ 2,153,624
Basic and diluted net (loss) income per share:
Loss from continuing operations (in dollars per share)	$ (0.04)	$ (0.09)	$ (0.23)	$ (0.08)
Income (loss) from discontinued operations, net of tax (in dollars per share)	0.02	(0.03)	(0.03)	28.84
Net (loss) income per share in Basic (in dollars per share)	(0.02)	(0.13)	(0.26)	28.76
Diluted net income (loss) per share:
Loss from continuing operations in diluted (in dollars per share)	(0.04)	(0.09)	(0.23)	(0.08)
Income (loss) from discontinued operations, net of tax (in dollars per share)	0.02	(0.03)	(0.03)	28.84
Net (loss) income per share in diluted (in dollars per share)	$ (0.02)	$ (0.13)	$ (0.26)	$ 28.76
Weighted average shares used in computing net income (loss) per share:
Basic (in shares)	63,432	74,989	68,494	74,879
Diluted (in shares)	63,432	74,989	68,494	74,879
Products
Revenue
Total revenue	$ 67,296	$ 42,688	$ 205,011	$ 138,006
Cost of revenue
Total cost of revenue	42,747	24,090	136,855	73,565
Services
Revenue
Total revenue	98,652	90,047	287,704	279,925
Cost of revenue
Total cost of revenue	$ 55,196	$ 49,045	$ 160,754	$ 146,897

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	$ (1,470)	$ (9,570)	$ (17,632)	$ 2,153,624
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments reclassed out of accumulated other comprehensive income related to discontinued operations				(16,567)
Net investment hedge currency translation adjustment, net of tax effects of $(75) and $(24,315) for the three and nine months ended June 30, 2023 and $13,815 and $16,733 for the three and nine months ended June 30, 2022	(218)	41,956	(70,478)	49,081
Foreign currency translation adjustments	1,876	(70,179)	113,140	(85,160)
Changes in unrealized gains (losses) on marketable securities, net of tax effects of $23 and $1,418 for the three and nine months ended June 30, 2023 and $(911) and $(1,809) for the three and nine months ended June 30, 2022	67	(2,898)	4,109	(5,306)
Actuarial gains, net of tax effects of $0 and $0 during the three and nine months ended June 30, 2023, $7 and $27 during the three and nine months ended June 30, 2022		26		108
Total other comprehensive income (loss), net of tax	1,725	(31,095)	46,771	(57,844)
Comprehensive income (loss)	$ 255	$ (40,665)	$ 29,139	$ 2,095,780

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract]
Net investment hedge currency translation adjustment, tax	$ (75)	$ 13,815	$ (24,315)	$ 16,733
Changes in unrealized losses on marketable securities, tax	23	(911)	1,418	(1,809)
Actuarial gains (losses), tax	$ 0	$ 7	$ 0	$ 27

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net income (loss)	$ (17,632)	$ 2,153,624
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	63,443	38,813
Stock-based compensation	10,091	10,715
Contingent consideration adjustment	(18,549)	600
Amortization and accretion on marketable securities	(6,942)	(7,048)
Deferred income taxes	(25,149)	24,207
Loss on extinguishment of debt		632
Purchase accounting impact on inventory	8,737
(Gain) loss on disposals of property, plant and equipment	37	(100)
Gain on divestiture, net of tax		(2,128,761)
Fees paid stemming from divestiture		(52,461)
Taxes paid stemming from divestiture		(431,600)
Changes in operating assets and liabilities:
Accounts receivable	29,028	(16,298)
Inventories	(4,104)	(61,345)
Accounts payable	(13,193)	(8,320)
Deferred revenue	2,496	8,580
Accrued warranty and retrofit costs	1,412	(28)
Accrued compensation and tax withholdings	(15,830)	13,835
Accrued restructuring costs	311	(126)
Other current assets and liabilities	(36,578)	(19,999)
Net cash used in operating activities	(22,422)	(475,680)
Cash flows from investing activities
Purchases of property, plant and equipment	(29,218)	(59,730)
Purchases of technology intangibles		(4,000)
Purchases of marketable securities	(236,194)	(1,525,993)
Sales and maturities of marketable securities	951,504	503,505
Proceeds from divestiture, net of cash transferred		2,926,286
Net Investment hedge settlement	29,313
Acquisitions, net of cash acquired	(386,508)
Net cash provided by investing activities	328,897	1,840,068
Cash flows from financing activities
Proceeds from issuance of common stock		3,461
Principal payments on debt		(49,725)
Common stock dividends paid		(7,494)
Payment for contingent consideration related to acquisition		(10,400)
Payment of finance leases	(181)	(355)
Stock repurchase	(672,116)
Withholding tax payments on net share settlements on equity awards	(4,924)
Net cash used in financing activities	(677,221)	(64,513)
Effects of exchange rate changes on cash and cash equivalents	65,610	(98,972)
Net (decrease) increase in cash, cash equivalents and restricted cash	(305,136)	1,200,903
Cash, cash equivalents and restricted cash, beginning of period	1,041,296	285,333
Cash, cash equivalents and restricted cash, end of period	736,160	1,486,236
Supplemental disclosures:
Cash paid for income taxes, net	$ 41,064	$ 452,461

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents of continuing operations	$ 733,369	$ 658,274
Short-term restricted cash	2,287	382,596
Long-term restricted cash included in other assets	504	426
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$ 736,160	$ 1,041,296
Restricted Cash, Noncurrent, Statement of Financial Position	Other assets	Other assets

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock Share Repurchase Program, Accelerated Share Repurchase Programs	Common Stock Share Repurchase Program, Open Market Share Repurchase Programs	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Treasury Stock Share Repurchase Program, Accelerated Share Repurchase Programs	Treasury Stock Share Repurchase Program, Open Market Share Repurchase Programs	Treasury Stock	Share Repurchase Program, Accelerated Share Repurchase Programs	Share Repurchase Program, Open Market Share Repurchase Programs	Total
Beginning Balance at Sep. 30, 2021			$ 878	$ 1,976,112	$ 19,351	$ (470,051)			$ (200,956)			$ 1,325,334
Beginning Balance (in shares) at Sep. 30, 2021			87,808,922
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes			$ 7	3,454								3,461
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)			642,301
Stock-based compensation				10,715								10,715
Common stock dividends declared						(7,494)						(7,494)
Net investment hedge currency translation adjustment, net of tax					49,081							49,081
Foreign currency translation adjustments reclassed out of accumulated other comprehensive income related to discontinued operations					(16,567)							(16,567)
Foreign currency translation adjustments					(85,160)							(85,160)
Changes in unrealized gains (losses) on marketable securities, net of tax					(5,306)							(5,306)
Actuarial loss, net of tax					108							108
Net income (loss)						2,153,624						2,153,624
Other						(10)						(10)
Ending Balance at Jun. 30, 2022			$ 885	1,990,281	(38,493)	1,676,069			(200,956)			3,427,786
Ending Balance (in shares) at Jun. 30, 2022			88,451,223
Beginning Balance at Mar. 31, 2022			$ 885	1,986,796	(7,398)	1,685,649			(200,956)			3,464,976
Beginning Balance (in shares) at Mar. 31, 2022			88,450,083
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)			1,140
Stock-based compensation				3,485								3,485
Net investment hedge currency translation adjustment, net of tax					41,956							41,956
Foreign currency translation adjustments					(70,179)							(70,179)
Changes in unrealized gains (losses) on marketable securities, net of tax					(2,898)							(2,898)
Actuarial loss, net of tax					26							26
Net income (loss)						(9,570)						(9,570)
Other						(10)						(10)
Ending Balance at Jun. 30, 2022			$ 885	1,990,281	(38,493)	1,676,069			(200,956)			3,427,786
Ending Balance (in shares) at Jun. 30, 2022			88,451,223
Beginning Balance at Sep. 30, 2022			$ 885	1,992,017	(83,916)	1,655,356			(200,956)			$ 3,363,386
Beginning Balance (in shares) at Sep. 30, 2022			88,482,125									75,020,256
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes			$ 2	(3,074)								$ (3,072)
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)			219,424
Share repurchases							$ (501,637)	$ (174,322)		$ (501,637)	$ (174,322)
Share repurchases (in shares)	(10,072,055)	(3,972,634)
Retirement of treasury shares			$ (140)	(675,819)					675,959
Stock-based compensation				10,091								10,091
Net investment hedge currency translation adjustment, net of tax					(70,478)							(70,478)
Foreign currency translation adjustments					113,140							113,140
Changes in unrealized gains (losses) on marketable securities, net of tax					4,109							4,109
Net income (loss)						(17,632)						(17,632)
Other						(85)						(85)
Ending Balance at Jun. 30, 2023			$ 747	1,323,215	(37,145)	1,637,639			(200,956)			$ 2,723,500
Ending Balance (in shares) at Jun. 30, 2023			74,656,860									61,194,991
Beginning Balance at Mar. 31, 2023			$ 826	1,495,118	(38,870)	1,639,109			(200,956)			$ 2,895,227
Beginning Balance (in shares) at Mar. 31, 2023			82,602,702
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes			$ 0	(18)								(18)
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)			8,713
Share repurchases							$ (1,637)	$ (174,322)		$ (1,637)	$ (174,322)
Share repurchases (in shares)	(3,981,921)	(3,972,634)
Retirement of treasury shares			$ (80)	(175,880)					175,959
Stock-based compensation				3,995								3,995
Net investment hedge currency translation adjustment, net of tax					(218)							(218)
Foreign currency translation adjustments					1,876							1,876
Changes in unrealized gains (losses) on marketable securities, net of tax					67							67
Net income (loss)						(1,470)						(1,470)
Ending Balance at Jun. 30, 2023			$ 747	$ 1,323,215	$ (37,145)	$ 1,637,639			$ (200,956)			$ 2,723,500
Ending Balance (in shares) at Jun. 30, 2023			74,656,860									61,194,991

CONDENSED CONSOLIDATED STATEM_7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)	9 Months Ended
	Jun. 30, 2022 $ / shares
Statement of Stockholders' Equity [Abstract]
Dividend declared per share (in dollars per share)	$ 0.10

Nature of Operations

Nature of Operations	9 Months Ended
	Jun. 30, 2023
Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Azenta, Inc. (“Azenta”, or the “Company”) is a leading global provider of sample exploration and management solutions for the life sciences industry. The Company supports its customers from research to clinical development with its sample management, automated storage, and genomic services expertise to help bring impactful therapies to market faster. Risks and Uncertainties The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its of new technological innovations, risk of disruption in its supply chain, the implementation of tariffs and export controls, inflation, dependence on key personnel, protection of proprietary technology and compliance with domestic and foreign regulatory authorities and agencies. The COVID-19 pandemic has had varying impacts on our financial results. In the first two years of the pandemic, any marginal adverse impact was more than offset by incremental orders related to virus research, COVID testing and vaccine development and commercialization. There has been limited COVID-related demand after the second fiscal quarter of 2022, and therefore, our revenue trends since then have been negatively impacted when compared to prior periods. Future impacts on the Company’s financial results are not fully determinable, as the continuing impact of the pandemic on the economy and markets which the Company serves is unknown, but will be dependent, in part, on future variants of the virus and vaccine effectiveness against these variants and new or prolonged government responses to the pandemic. The Company’s financial results will also depend on variables including reduced demand from its customers, the degree that the supply chain may be constrained which could impact its delivery of products and services and the potential negative impact on its operations if there is an outbreak among the Company’s employees, as well as the amount of incremental demand caused by research and treatments in the areas of COVID-19 or related threats.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and all entities where it has a controlling financial interest and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying year-end balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023, and the results of its operations for the three and nine months ended June 30, 2023 and 2022, and cash flows for the nine months ended June 30, 2023 and 2022, respectively. Certain information and disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022 filed with the U.S. Securities and Exchange Commission on November 25, 2022 (the “2022 Annual Report on Form 10-K”). Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect amounts reported in the financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, contingent consideration liabilities related to business combinations, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition, will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 in the analysis of its financial statements. Business Combinations The Company accounts for business acquisitions using the purchase method of accounting, in accordance with which assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. The fair value of the consideration paid, including contingent consideration, is assigned to the assets acquired and liabilities assumed based on their respective fair values. Goodwill represents the excess of the purchase price over the estimated fair values of the assets acquired and liabilities assumed. Significant judgment is used in determining fair values of assets acquired and liabilities assumed and contingent consideration, as well as intangibles and their estimated useful lives. Fair value and useful life determinations may be based on, among other factors, estimates of future expected cash flows and appropriate discount rates used in computing present values. These judgments may materially impact the estimates used in allocating acquisition date fair values to assets acquired and liabilities assumed, as well as our current and future operating results. Actual results may vary from these estimates and may result in adjustments to goodwill and acquisition date fair values of assets and liabilities during a measurement period or upon a final determination of asset and liability fair values, whichever occurs first. Adjustments to fair values of assets and liabilities made after the end of the measurement period are recorded within our operating results. Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled. Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expense)” in the Condensed Consolidated Statements of Operations. Net foreign currency transaction and remeasurement gains were $0.1 million and $0.3 million for the three months ended June 30, 2023 and 2022, respectively. Net foreign currency transaction and remeasurement losses were $2.7 million and $2.9 million during the nine months ended June 30, 2023 and 2022, respectively. The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets and presented as “Foreign currency translation adjustments” in the Condensed Consolidated Statements of Comprehensive Income (Loss). Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expense)” in the Condensed Consolidated Statements of Operations and are as follows for the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ June 30, ​ June 30, ​ 2023 2022 2023 2022 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ 182 ​ $ 848 ​ $ (1,930) ​ $ 1,903 ​ The fair values of the forward contracts are recorded in the Condensed Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts. Hedging Activities On February 1, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $1.0 billion for €915.0 million at a weighted average interest rate of 1.20% . The designated notional amount was $960.0 million and the actual interest rate was 1.28% . The 1.28% rate was in the range of the market value for that day and was the true interest rate on the notional amount. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries requiring an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap on February 1, 2023, the Company delivered a notional amount of €852.0 million and received a notional amount of $960.0 million at an exchange rate of 1.13 , which included realization of a gain of $29.3 million, which was recorded in “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. On February 1, 2023, the Company entered into another cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $436.0 million for €400.0 million at a weighted average interest rate of 1.66%. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on February 1, 2024. The cross-currency swaps are marked to market at each reporting period, representing the fair values of the cross-currency swap and any changes in fair value are recognized as a component of “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. Interest accrued on the cross-currency swap is recorded within “Interest income” in the Condensed Consolidated Statements of Operations. For the three and nine months ended June 30, 2023, the Company recorded a net loss of $0.2 and $70.5 million, respectively, to “Accumulated other comprehensive income (loss)” and recorded “Interest income” of $1.8 million and $7.1 million on these instruments for the three and nine months ended June 30, 2023, respectively. Marketable Securities The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the Condensed Consolidated Balance Sheets. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. Unrealized gains and losses are excluded from earnings and reported as a separate component of “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets until the security is sold or matures. Gains or losses realized from sales of marketable securities are computed based on the specific identification method and recognized as a component of “Other income (expense)” in the accompanying unaudited Condensed Consolidated Statements of Operations. The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value. The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term prospects of the issuer, the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of its amortized cost basis. If the Company believes that an other-than-temporary decline in fair value has occurred, it writes down the investment to its fair value and recognizes the credit loss in earnings and the non-credit loss in accumulated other comprehensive income or loss. Fair Value Measurement The Company measures certain financial assets and liabilities, including cash equivalents, available-for-sale securities, accounts receivable, accounts payable, contingent consideration liability and derivative instruments at fair value. The Company applies a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following levels of inputs may be used to measure fair value: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible as of the reporting date. Active markets are those in which transactions for the asset and liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. The fair value hierarchy gives the highest priority to Level 1 inputs. ● Level 2: Observable inputs other than prices included in Level 1, including quoted prices for similar assets or liabilities in active markets and quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3: Unobservable inputs that are significant to the fair value of the assets or liabilities and reflect an entity’s own assumptions in pricing assets or liabilities since they are supported by little or no market activity. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, as well as considering counterparty credit risk in its assessment of fair value. The Company measures certain assets, including the cost and equity method investments, at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparable prices, and discounted cash flow projections. An impairment charge is recorded when the cost of the investment exceeds its fair value and this condition is determined to be other-than-temporary Accounts Receivable and Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on several factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Condensed Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in “Revenue” in the Condensed Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the Condensed Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the Condensed Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the Condensed Consolidated Balance Sheets. Goodwill Goodwill represents the excess of purchase price over the fair value of net tangible and identifiable intangible assets of businesses acquired by the Company. Goodwill is tested for impairment annually or more often if impairment indicators are present at the reporting unit level. The Company elected April 1 st Application of the goodwill impairment test requires significant judgment based on market and operational conditions at the time of the evaluation, including management’s best estimate of future business activity and the related estimates of future cash flows from the reporting units that include the associated goodwill. These periodic evaluations could cause management to conclude that impairment factors exist, requiring an adjustment of these assets to their then current fair market values. Future business conditions and/or activity could differ materially from the projections made by management which could result in impairment charges. The goodwill impairment test is performed at the reporting unit level. A reporting unit is either an operating segment or one level below it, which is referred to as a “component”. The level at which the impairment test is performed requires an assessment of whether the operations below an operating segment constitute a self-sustaining business, in which case testing is generally performed at this level. T he Company first assesses qualitative factors to determine whether the existence of events or circumstances indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines, based on this assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying value, management performs a quantitative goodwill impairment test by comparing the reporting unit’s fair value with its carrying value. An impairment loss is recognized for the amount by which the reporting unit’s carrying value exceeds its fair value, up to the total amount of goodwill allocated to the reporting unit. We determine fair values of our reporting units based on an income approach in accordance with the discounted cash flow method, (the “DCF Method”). The DCF Method is based on projected future cash flows and terminal value estimates discounted to their present values. Terminal value represents the present value an investor would pay on the valuation date for the rights to the cash flows of the business for the years subsequent to the discrete cash flow projection period. We consider the DCF Method to be the most appropriate valuation technique since it is based on management’s long-term financial projections. In addition to determining the fair value of our reporting units based on the DCF Method, we also compare the aggregate values of our net corporate assets and reporting unit fair values to our overall market capitalization and use certain market-based valuation techniques to assess the reasonableness of the reporting unit fair values determined in accordance with the DCF Method. The key inputs used in the DCF Method include revenue growth rates, gross margin percentages, selling, general and administrative expense percentages and discount rates that are at or above our weighted average cost of capital. We derive discount rates that are commensurate with the risks and uncertainties inherent in the respective reporting units and our internally developed projections of future cash flows. Application of the goodwill impairment test requires judgment based on market and operational conditions at the time of the evaluation, including management’s best estimates of the reporting unit’s future business activity and the related estimates and assumptions of future cash flows from the assets that include the associated goodwill. Different assumptions of revenue growth rates, gross margin percentages, selling, general and administrative expense percentages and the discount rate used in the DCF Method could result in different estimates of the reporting unit’s fair value as of each testing date. Warranty Obligations The Company establishes reserves for estimated costs of product warranties based on historical information. Product warranty reserves are recorded at the time product revenue is recognized, and retrofit accruals are recorded at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company. Stock-Based Compensation The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant. For awards that vest based on service conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period. For awards that vest subject to performance conditions, the Company recognizes stock-based compensation expense ratably over the performance period if it is probable that performance condition will be met and adjusts for the percentage of shares probable of achieving the performance goals. Each quarter, management assesses the probability of achieving the performance goals. The Company makes estimates of stock award forfeitures and the number of awards expected to vest. The Company considers many factors in developing forfeiture estimates, including award types, employee classes and historical experience. Current estimates may differ from actual results and future changes in estimates. Recently Issued Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. The ASUs provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (“LIBOR”) and other interbank offered rates to alternative reference rates. The provisions of the ASUs were only available until December 31, 2022, when the reference rate replacement activity was expected to be completed. Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in the annual consolidated financial statements for fiscal 2023. In June 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) Other For further information regarding the Company’s significant accounting policies, please refer to Note 2, Summary of Significant Accounting Policies

Discontinued Operations

Discontinued Operations	9 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. Discontinued Operations Disposition of the Semiconductor Automation Business On September 20, 2021, the Company entered into a definitive agreement to sell its semiconductor automation business to Thomas H. Lee Partners, L.P. (“THL”) and the Company determined that the semiconductor automation business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results are reflected in the condensed consolidated financial statements as a discontinued operation, and assets and liabilities were classified as assets and liabilities held for sale. On February 1, 2022, the Company completed the sale of the semiconductor automation business for $2.9 billion in cash. As part of the transaction, the Company recorded an $18.1 million liability related to retention bonuses and cash settled stock-based awards for former employees of the Company that were conveyed with the transaction. The Company paid $0.6 million of these payments during the year ended September 30, 2022 and remitted the remaining payments to THL in November 2022, and THL directly paid the Company’s former employees. Following the completion of the sale, the Company no longer serves the semiconductor market. In connection with the closing of the sale, the Company and THL entered into a transition services agreement under which both the Company and THL will provide each other certain transition services related to finance and accounting, information technology, human resources, compliance, facilities, legal and research and development support, for time periods ranging from three During the three months ended June 30, 2023, the Company recorded a $1.0 million gain on divestiture. The following table presents the financial results of discontinued operations with respect to the semiconductor automation business for the three and nine months ended June 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ ​ Nine Months Ended June 30, ​ ​ 2022 ​ 2022 Revenue ​ ​ ​ ​ ​ Products ​ $ - ​ $ 244,962 Services ​ ​ - ​ ​ 19,468 Total revenue ​ ​ - ​ ​ 264,430 Cost of revenue ​ ​ ​ ​ ​ ​ Products ​ ​ - ​ ​ 141,165 Services ​ ​ - ​ ​ 11,159 Total cost of revenue ​ ​ - ​ ​ 152,324 Gross profit ​ ​ - ​ ​ 112,106 Operating expenses ​ ​ ​ ​ ​ ​ Research and development ​ ​ - ​ ​ 18,486 Selling, general and administrative ​ ​ 480 ​ ​ 30,622 Total operating expenses ​ ​ 480 ​ ​ 49,108 Operating (loss) income ​ ​ (480) ​ ​ 62,998 (Loss) gain on divestiture ​ ​ (990) ​ ​ 2,560,384 (Loss) income before income taxes ​ ​ (1,470) ​ ​ 2,623,382 Income tax provision ​ ​ 1,085 ​ ​ 463,785 Net (loss) income from discontinued operations ​ $ (2,555) ​ $ 2,159,597 ​ The following table presents the significant non-cash items and capital expenditures for the discontinued operations with respect to the semiconductor automation business that are included in the Condensed Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ 2022 ​ ​ 2022 Capital expenditures ​ $ - ​ $ 2,862 Stock-based compensation ​ $ - ​ $ 8,032 ​ ​ ​ ​ ​

Business Combinations

Business Combinations	9 Months Ended
	Jun. 30, 2023
Business Combinations [Abstract]
Acquisitions	4. Business Combinations The Company recorded the assets acquired and liabilities assumed related to the following acquisitions at their fair values as of the acquisition date, from a market participant’s perspective. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The measure period to finalize the fair values is completed within one year after the respective acquisition date. Acquisitions Completed in Fiscal Year 2023 Ziath Ltd On February 2, 2023, the Company acquired Ziath, Ltd. and its subsidiaries (“Ziath”). Based in Cambridge, United Kingdom, Ziath is a leading provider of 2D barcode readers for life science applications. Founded in 2005, Ziath’s innovative 2D barcode readers are a key component of the laboratory automation workflow serving pharmaceutical, biotechnology and academic customers worldwide. Ziath will enhance the Company’s offerings, which support the entire lifecycle of sample management from specimen collection to sample registration, storage and processing. The acquisition was completed at a purchase price of $16.0 million, net of cash acquired. The acquired business is included in the Life Sciences Products segment. The allocation of the consideration included $12.0 million of goodwill, $4.1 million of technology, $1.1 million of deferred tax liability, $0.6 million of customer relationships, $0.3 million of trademarks, and several other assets and liabilities. The weighted average life of completed technology is 10 years, customer relationships is 13 years, and trademarks is 13 years. The goodwill represents the Company’s ability to provide a differentiated technology enabling high throughput scanning of varied formats of consumables. The goodwill is not expected to be deductible for income tax purposes. The Company did not present pro forma financial information for its condensed consolidated results of operations for the acquisition because such results are immaterial. B Medical Systems S.á r.l. On October 3, 2022, the Company acquired B Medical Systems S.á r.l. and its subsidiaries ("B Medical"), for a purchase price of $432.2 million including contingent consideration, which the Company estimated to be $17.0 million as of the measurement date. B Medical is a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. B Medical’s results of operations are reported in the Company’s Life Sciences Products segment from the date of acquisition. The Company paid a total initial cash purchase price at closing of $424.0 million, as adjusted for cash acquired and other items pursuant to the acquisition agreement. B Medical Systems Holdings S.A (the “Seller”) is eligible to earn up to €50.0 million in contingent consideration based upon achievement of certain financial metrics by B Medical. The Company repaid B Medical’s outstanding debt of $43.1 million prior to September 30, 2022 which is included in the purchase price and was classified in prepaid assets as of September 30, 2022. In addition, the Company recorded $381.0 million in short-term restricted cash as of September 30, 2022, which was reserved to complete the acquisition which occurred on October 3, 2022. The contingent consideration payment from the Company to the Seller is based on achievement of certain revenue targets over the one-year period from October 3, 2022 to September 30, 2023. The Company recorded the estimated fair value of the contingent consideration liability utilizing a Monte Carlo simulation that incorporates revenue projections, revenue growth rates of comparable companies, implied volatility and a risk adjusted discount rate. Each quarter, the Company is required to remeasure the fair value of this liability as assumptions change over time and any resulting adjustments in the fair value of this liability are recorded in “Operating expenses” in the Condensed Consolidated Statements of Operations. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement. This fair value measurement is directly impacted by the Company’s estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth is higher or lower than the estimates within the fair value measurement, the Company would record additional charges or gains. As of June 30, 2023, the fair value of the contingent consideration liability was determined to be zero as compared to $1.4 million as of March 31, 2023. The purchase price was allocated to B Medical’s tangible and identifiable intangible assets acquired and liabilities assumed based on the estimated fair values as of October 3, 2022, as set forth below (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Accounts receivable ​ $ 19,549 Inventory ​ 49,497 Other assets ​ 10,769 Property plant and equipment ​ 54,149 Identifiable Intangible Assets: ​ ​ Completed technology ​ 100,600 Trademarks ​ 5,500 Customer relationships ​ 36,700 Backlog ​ 600 Other liabilities ​ (31,489) Deferred income taxes, net ​ ​ (42,974) Goodwill ​ ​ 229,260 Total purchase price, net of cash acquired ​ $ 432,160 ​ During the three months ended June 30, 2023, the purchase price, net of cash acquired, remains the same. The Company recorded an adjustment during the three months ended June 30, 2023 which resulted in a net increase to goodwill of $0.4 million related to a $0.4 million increase in accrued liabilities. In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, and historical financial performance and estimates of future performance of B Medical’s business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the assets acquired and liabilities assumed. As part of the purchase price allocations, the Company determined the identifiable intangible assets were completed technology, trademarks, customer relationships and backlog. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a rate of 13%. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked to the implied rate of return from the transaction and the weighted average cost of capital. The weighted average life of completed technology is 10 years, customer relationships is 16 years, trademarks is five years and backlog is one year. The intangible assets acquired are amortized over their respective weighted average life using methods that approximate the pattern in which the economic benefits are expected to be realized. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Goodwill of $229.3 million largely reflects the potential expansion of the Company's cold chain capabilities in the Company’s Life Sciences Products segment by adding differentiated solutions for reliable and traceable transport of temperature-controlled specimens. The goodwill is not expected to be deductible for income tax purposes. The following financial information reflects our condensed consolidated results from B Medical (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ 2023 ​ 2023 ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 27,275 ​ $ 84,552 Net (loss) income ​ $ (5,169) ​ $ (18,174) ​ The Company incurred $3.6 million in transaction costs related to the acquisition of which $0.0 million and $3.6 million were incurred during the three and nine months ended June 30, 2023, respectively. The following unaudited pro forma financial information reflects our condensed consolidated results of operations as if the acquisition had taken place on October 1, 2021 (in thousands). The unaudited pro forma financial information is not necessarily indicative of the results of operations that we would have reported had the transaction occurred at the beginning of these periods nor is it necessarily indicative of future results. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 165,948 ​ $ 152,641 ​ $ 492,715 ​ $ 510,074 Net (loss) income ​ $ 492 ​ $ (14,605) ​ $ (8,128) ​ $ 2,135,512 ​ The unaudited pro forma earnings for the three and nine months ended June 30, 2023 have been adjusted to exclude $2.0 million and $5.9 million, respectively, of property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense of $0.0 million and $3.6 million, respectively, of non-recurring acquisition related transaction costs. To present our condensed consolidated results of operations as if the acquisition had taken place on October 1, 2021, the unaudited pro forma earnings for the three and nine months ended June 30, 2022 have been adjusted to include $6.2 million and $18.9 million, respectively, of property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense. Non-recurring acquisition related items and significant GAAP adjustments in the three and nine months ended June 30, 2022 include $0.0 million and $8.9 million, respectively, of transactions costs, exclude $0.2 million and $5.9 million, respectively, of debt interest expense, include $0.0 million and $1.4 million, respectively, expense of capitalized research and development costs, and exclude $1.6 million and $6.4 million of adjustments for tax impact, respectively. The pro forma financial information does not include any anticipated cost savings or other effects of the integration of B Medical. Accordingly, the unaudited pro forma financial information does not necessarily reflect the actual results that would have occurred, nor is it necessarily indicative of future results of operations. Acquisition Completed in Fiscal Year 2022 Barkey Holding GmbH On July 1, 2022, the Company acquired Barkey Holding GmbH and its subsidiaries (“Barkey”), a leading provider of controlled-rate thawing devices for customers in the medical, biotechnology and pharmaceutical industries, head quartered in Leopoldshöhe, Germany. The financial results for Barkey are included within the Life Sciences Products segment. The total cash purchase price of the acquisition was $84.8 million, net of cash acquired. The acquisition added innovative products and capabilities that extend the Company’s extensive cold chain of condition portfolio of products and services, while also expanding the Company’s customer reach in the fast-growing cell and gene therapy space. The allocation of the consideration included $3.0 million of customer relationships, $29.0 million of technology, $57.8 million of goodwill, $9.8 million of deferred tax liabilities, and several other assets and liabilities. The weighted useful life of all the intangible assets acquired is 15 years. The goodwill and intangibles are not tax deductible. The Company did not present pro forma financial information for its condensed consolidated results of operations for the acquisition because such results are immaterial.

Marketable Securities

Marketable Securities	9 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	5. Marketable Securities The Company had sales and maturities of marketable securities of $223.3 million and $951.5 million in the three and nine months ended June 30, 2023, respectively. There were $499.8 million and $503.5 million sales and maturities of marketable securities in the three and nine months ended June 30, 2022, respectively. There were immaterial and $0.8 million realized losses on the sale and maturities of marketable securities in the three and nine months ended June 30, 2023, respectively. There were immaterial realized gains on the sale and maturities of marketable securities in the three and nine months ended June 30, 2022. Amortized cost and the fair value, including accrued interest receivable and unrealized gains (losses) on the short-term and long-term marketable securities as of June 30, 2023 and September 30, 2022 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value June 30, 2023: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 311,618 ​ $ (3,731) ​ $ 1 $ 307,888 Bank certificates of deposits ​ ​ 9,078 ​ ​ (194) ​ ​ — ​ ​ 8,884 Corporate securities ​ ​ 248,309 ​ ​ (5,186) ​ ​ — ​ ​ 243,123 Municipal securities ​ 20 ​ ​ (1) ​ ​ — ​ 19 ​ ​ $ 569,025 ​ $ (9,112) ​ $ 1 ​ $ 559,914 September 30, 2022: ​ ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies ​ $ 804,774 $ (6,163) $ 21 ​ $ 798,632 Bank certificates of deposits ​ ​ 8,335 ​ ​ (158) ​ ​ 1 ​ ​ 8,178 Corporate securities ​ ​ 406,270 ​ ​ (8,113) ​ ​ — ​ ​ 398,157 Municipal securities ​ 59,043 ​ ​ (226) ​ ​ — ​ 58,817 ​ ​ $ 1,278,422 ​ $ (14,660) ​ $ 22 ​ $ 1,263,784 ​ The fair values of the marketable securities by contractual maturities as of June 30, 2023 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ $ 394,811 ​ $ 390,492 Due after one year through five years ​ 171,049 ​ 166,257 Due after five years through ten years ​ ​ — ​ ​ — Due after ten years ​ 3,165 ​ 3,165 Total marketable securities ​ $ 569,025 ​ $ 559,914 ​ Expected maturities could differ from contractual maturities because the security issuers may have the right to prepay obligations without prepayment penalties. Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. The Company does not believe any unrealized losses represent impairments based on our evaluation of the available evidence.

Accounts Receivable, Net

Accounts Receivable, Net	9 Months Ended
	Jun. 30, 2023
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Accounts Receivable, Net	6. Accounts Receivable, Net The following is a summary of accounts receivable, net as of June 30, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ September 30, ​ 2023 2022 Accounts receivable ​ $ 171,422 ​ $ 168,920 Less allowance for expected credit losses ​ (8,403) ​ (5,162) Accounts receivable, net ​ $ 163,019 ​ $ 163,758 ​ The allowance for expected credit losses for the nine months ended June 30, 2023 and fiscal year ended September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended ​ Year ended ​ ​ June 30, 2023 ​ September 30, 2022 ​ ​ ​ ​ ​ ​ ​ Balance at Beginning of Period ​ $ 5,162 ​ $ 4,318 Provisions ​ 6,963 ​ 3,536 Reversals of Bad Debt Expense ​ ​ (3,652) ​ ​ (2,278) Write-offs and Adjustments ​ (70) ​ ​ (414) Balance at End of Period ​ $ 8,403 ​ $ 5,162

Inventories

Inventories	9 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	7. Inventories The following is a summary of inventories at June 30, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ June 30, September 30, ​ 2023 2022 ​ ​ Raw materials and purchased parts $ 65,380 $ 39,685 Work-in-process ​ 8,088 ​ 4,816 Finished goods ​ 68,634 ​ 41,043 Total inventories $ 142,102 $ 85,544 ​ Reserves related to write downs or adjustments of inventory to net realizable value were $4.3 million and $4.1 million, respectively, at June 30, 2023 and September 30, 2022.

Capitalized Software Costs

Capitalized Software Costs	9 Months Ended
	Jun. 30, 2023
Capitalized Computer Software, Net [Abstract]
Capitalized Software Costs	8. Capitalized Software Costs At June 30, 2023 and September 30, 2022, the Company had cumulative capitalized direct costs of $29.4 million and $26.9 million, respectively, associated with the development of software for its internal use. As of June 30, 2023, this balance included $10.8 million associated with software assets that are still in the development stage and not yet placed in service. During the three and nine months ended June 30, 2023, the Company capitalized direct costs associated with the development of software for its internal use of $0.7 million and $2.6 million, respectively, as compared to $1.2 million and $2.8 million, respectively, during the corresponding periods of the prior fiscal year.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets In the second quarter of fiscal 2023, as part of the Company’s routine long-term planning process, the Company assessed several events and circumstances that could affect the significant inputs used to determine the fair value of its reporting units, including updates to forecasted margins and cash flows, and the overall change in the economic climate since its last impairment assessment. The Company considered impairment indicators and determined it appropriate to perform a quantitative assessment of its reporting units as of March 31, 2023. The estimated fair value of the Life Sciences Services and Life Sciences Products reporting units exceeded their respective carrying values by approximately 24% and 17%, respectively, as of March 31, 2023. Therefore, the Company concluded there was no impairment to goodwill as of March 31 or April 1, 2023. The Company performed a qualitative goodwill impairment assessment during the third quarter of fiscal 2023 and determined that there were no events or circumstances during the period to indicate an additional quantitative goodwill impairment assessment was required for the third quarter of fiscal 2023. In the event the financial performance of the reporting units does not meet management’s expectations in the future, there is a change to the Company’s reportable segments, the Company experiences a prolonged macroeconomic or market downturn, declines in the Company’s stock price, or there are other negative revisions to key assumptions used in the DCF Method, the Company may be required to perform additional impairment analyses and could be required to recognize an impairment charge. Refer to the Notes to our audited consolidated financial statements included in the section titled “Financial Statements and Supplementary Data” in Part II, Item 8 of our 2022 Annual Report on Form 10 K for further information on the goodwill impairment testing performed during fiscal year 2022. The changes in the Company’s goodwill by reportable segment for the nine months ended June 30, 2023 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance - September 30, 2022 ​ $ 154,612 ​ $ 359,011 ​ $ 513,623 Acquisitions ​ 229,260 ​ — ​ 229,260 Currency translation adjustments ​ ​ 50,655 ​ ​ 85 ​ ​ 50,740 Balance - June 30, 2023 ​ $ 434,527 ​ $ 359,096 ​ $ 793,623 ​ During the nine months ended June 30, 2023, the Company recorded goodwill related to the B Medical and Ziath acquisitions of $229.3 million. The components of the Company’s identifiable intangible assets as of June 30, 2023 and September 30, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ September 30, 2022 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 8,996 ​ $ 8,928 ​ $ 68 ​ $ 1,225 ​ $ 1,106 ​ $ 119 Completed technology ​ 252,424 ​ 84,206 ​ 168,218 ​ 99,525 ​ 37,991 ​ 61,534 Trademarks and trade names ​ 8,909 ​ 3,173 ​ 5,736 ​ 400 ​ 41 ​ 359 Non-competition agreements ​ ​ 731 ​ ​ 586 ​ ​ 145 ​ ​ 681 ​ ​ 439 ​ ​ 242 Customer relationships ​ 321,155 ​ 183,943 ​ 137,212 ​ 246,949 ​ 130,802 ​ 116,147 Other intangibles ​ ​ 904 ​ ​ 228 ​ ​ 676 ​ ​ 202 ​ ​ 202 ​ ​ — Total ​ $ 593,119 ​ $ 281,064 ​ $ 312,055 ​ $ 348,982 ​ $ 170,581 ​ $ 178,401 ​ During the nine months ended June 30, 2023, the Company recorded intangible assets related to the B Medical and Ziath acquisitions of $147.5 million. Amortization expense for intangible assets was $12.2 million and $7.6 million, respectively, for the three months ended June 30, 2023 and 2022. Amortization expense for intangible assets was $36.1 million and $23.4 million, respectively, for the nine months ended June 30, 2023 and 2022. Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2023 the subsequent five fiscal years and thereafter is as follows (in thousands): ​ ​ ​ ​ 2023 ​ $ 11,366 2024 ​ 50,664 2025 ​ 49,292 2026 ​ 45,908 2027 ​ ​ 37,706 2028 ​ ​ 31,219 Thereafter ​ ​ 85,900 Total ​ $ 312,055 ​

Warranty and Retrofit Costs

Warranty and Retrofit Costs	9 Months Ended
	Jun. 30, 2023
Product Warranties Disclosures [Abstract]
Warranty and Retrofit Costs	10. Warranty and Retrofit Costs The following is a summary of product warranty and retrofit activity for the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at Beginning of Period ​ $ 5,380 ​ $ 2,491 ​ $ 2,890 ​ $ 2,330 ​ Adjustment for Acquisitions ​ ​ — ​ ​ — ​ ​ 2,303 ​ ​ — ​ Accruals ​ ​ 2,407 ​ ​ 663 ​ ​ 3,936 ​ ​ 1,875 ​ Cost Incurred ​ ​ (1,529) ​ ​ (630) ​ ​ (2,871) ​ ​ (1,681) ​ Balance at End of Period ​ $ 6,258 ​ $ 2,524 ​ $ 6,258 ​ $ 2,524

Restructuring

Restructuring	9 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring	11. Restructuring The restructuring accrual at the beginning of fiscal year 2023 was $0.5 million and was $0.8 million as of June 30, 2023. In the second quarter of 2023 the Company announced a cost savings plan to position the Company to meet the needs of their customers and accelerate growth of the business. In the third quarter of fiscal 2023, the Company announced a reorganization and another cost savings plan. The change in the accrual balance was primarily due to accruals offset by payments related to the separation of personnel due to reorganization and cost reduction efforts. Costs from these actions are expected to be fully realized by the end of calendar 2023. The restructuring accrual at the beginning of fiscal year 2022 was $0.3 million and the ending accrual balance as of September 30, 2022 was $0.5 million. The change in the accrual balance was primarily due to accruals and payments related to the separation of personnel due to the reorganization and cost reduction efforts.

Leases

Leases	9 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	12. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate in North America, Europe, and Asia. Non-real estate leases are primarily related to vehicles and office equipment. Lease expiration dates range between 2023 and 2043. The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ $ 3,332 ​ $ 2,468 ​ $ 9,450 ​ $ 7,028 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ 183 ​ ​ 18 ​ ​ 409 ​ ​ 147 ​ Interest on lease liabilities ​ ​ 12 ​ ​ - ​ ​ 26 ​ ​ 5 ​ Total finance lease costs ​ ​ 195 ​ ​ 18 ​ ​ 435 ​ ​ 152 ​ Total operating and finance lease costs ​ ​ 3,527 ​ ​ 2,486 ​ ​ 9,885 ​ ​ 7,180 ​ Variable lease costs ​ ​ 752 ​ ​ 783 ​ ​ 2,764 ​ ​ 2,056 ​ Short-term lease costs ​ ​ 415 ​ ​ 640 ​ ​ 1,009 ​ ​ 1,357 ​ Sublease income ​ ​ (2) ​ ​ - ​ ​ (6) ​ ​ - ​ Total lease costs ​ $ 4,692 ​ $ 3,909 ​ $ 13,652 ​ $ 10,593 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ September 30, 2022 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ ​ ​ ​ $ 67,352 ​ $ 54,059 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ $ 8,675 ​ $ 6,924 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ 61,799 ​ ​ 49,227 ​ Total operating lease liabilities ​ ​ ​ ​ ​ ​ ​ $ 70,474 ​ $ 56,151 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ ​ ​ ​ $ 4,511 ​ $ 2,476 ​ Accumulated amortization ​ ​ ​ ​ ​ ​ ​ ​ (2,501) ​ ​ (2,276) ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ $ 2,010 ​ $ 200 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ $ 673 ​ $ 96 ​ Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ 1,467 ​ ​ 98 ​ Total finance lease liabilities ​ ​ ​ ​ ​ ​ ​ $ 2,140 ​ $ 194 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ 11.22 ​ ​ 10.82 ​ Finance leases ​ ​ ​ ​ ​ ​ ​ ​ 3.54 ​ ​ 2.19 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ 4.21 % ​ 3.93 % Finance leases ​ ​ ​ ​ ​ ​ ​ ​ 2.50 % ​ 1.29 % ​ Supplemental cash flow information related to leases was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows - operating leases ​ $ 2,947 ​ $ 2,116 ​ $ 7,895 ​ $ 5,715 ​ Operating cash flows - finance leases ​ $ 12 ​ $ - ​ $ 26 ​ $ 4 ​ Financing cash flows - finance leases ​ $ 169 ​ $ 43 ​ $ 377 ​ $ 360 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 6,585 ​ $ 122 ​ $ 13,021 ​ $ 7,612 ​ Finance leases ​ $ 576 ​ $ - ​ $ 1,672 ​ $ - ​ ​ ​ Future lease payments for operating and finance leases as of June 30, 2023 were as follows for the remainder of fiscal year 2023, the subsequent five fiscal years and thereafter (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases Operating Leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ $ 190 ​ $ 2,937 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ 711 ​ ​ 11,107 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ 619 ​ ​ 10,797 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ 453 ​ ​ 8,311 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ 217 ​ ​ 7,875 ​ 2028 ​ ​ ​ ​ ​ ​ ​ ​ 38 ​ ​ 7,548 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ 9 ​ ​ 42,672 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ 2,237 ​ ​ 91,247 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ (97) ​ ​ (20,773) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ $ 2,140 ​ $ 70,474 ​ ​ ​ As of June 30, 2023, the Company had entered into leases that had not commenced with future lease payments of $9.3 million. These leases are not reflected in the ROU asset and lease liability in the Condensed Consolidated Balance Sheets. These leases commence in the fourth quarter of fiscal 2023. ​

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Jun. 30, 2023
Stockholders' Equity
Stockholders' Equity	13. Stockholders’ Equity On November 4, 2022, the Company’s Board of Directors terminated On November 23, 2022, the Company executed an ASR agreement (the “ASR Agreement”) with JPMorgan Chase Bank, National Association (the “Dealer”) to repurchase an aggregate of up to $500.0 million of the Company’s common stock After giving effect to the ASR Agreement, $1.0 billion of the amount authorized remained available for additional repurchases of the Company’s common stock. Following the final termination of the ASR Agreement in April 2023, new arrangements commenced under which the Company expects to repurchase up to an additional $500.0 million shares of common stock in open market purchases, subject to market and business conditions, legal requirements, and other factors. The Company acquired 4.0 million shares of its common stock in the third quarter of fiscal 2023 through open market purchases totaling $172.1 million (excluding fees, commissions, and excise tax) under these new arrangements. These shares of common stock repurchased by the Company were retired, accounted for as a reduction to stockholders’ equity in the Condensed Consolidated Balance Sheets and treated as a repurchase of common stock for purposes of calculating earnings per share as of the applicable settlement dates. Effective January 1, 2023, all corporate share repurchases are subject to a one percent excise tax on the value of the repurchase, net of share issuances, subject to certain exclusions. The excise tax was part of The Inflation Reduction Act passed by the U.S. government in 2022. The Company accrued

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	14. Revenue from Contracts with Customers Disaggregated Revenue The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ ​ ​ ​ 2023 ​ 2022 ​ ​ 2023 ​ 2022 Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products, excluding B Medical ​ ​ ​ $ 47,810 ​ $ 47,369 ​ $ 139,386 ​ $ 150,861 B Medical ​ ​ ​ ​ 26,761 ​ ​ - ​ ​ 83,705 ​ ​ - Sample Repository Solutions ​ ​ ​ ​ 27,531 ​ ​ 26,000 ​ ​ 82,452 ​ ​ 78,806 Genomic Services ​ ​ ​ ​ 63,846 ​ ​ 59,366 ​ ​ 187,172 ​ ​ 188,264 Total revenue ​ ​ ​ $ 165,948 ​ $ 132,735 ​ $ 492,715 ​ $ 417,931 ​ Contract Balances Accounts Receivable. Contract Assets. Contract Liabilities. Remaining Performance Obligations. obligations as revenue; the Company will recognize revenue associated with these performance obligations as transfer of control occurs (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining performance obligations ​ $ 62,778 ​ $ 24,654 ​ $ 87,432 ​ Cost to Obtain and Fulfill a Contract The Company capitalizes sales commissions when incurred if they are (i) incremental costs of obtaining a contract, (ii) expected to be recovered and (iii) have an expected amortization period that is greater than one year. As part of the Company’s cumulative effect adjustment upon the initial adoption of revenue recognition standards under GAAP, incremental costs associated with obtaining a contract were capitalized and are classified as deferred commissions in the Condensed Consolidated Balance Sheets. These amounts are being amortized over a 60-month period, which represents the average period of contract performance. The Company did not capitalize any sales commissions during the nine months ended June 30, 2023 and 2022 as the amount of sales commissions that qualified for capitalization during the reporting period was immaterial. Sales commissions incurred during the reporting period were expensed as incurred and are recorded within “Selling, general and administrative” expenses in the Condensed Consolidated Statements of Operations. None of the costs the Company incurs to fulfill customer contracts meet the capitalization criteria. The Company accounts for shipping and handling activities as fulfillment activities and recognizes the associated expense when control of the product has transferred to the customer.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jun. 30, 2023
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	15. Stock-Based Compensation The Company may issue to eligible employees options to purchase shares of the Company’s common stock, restricted stock units and other equity incentives, which vest upon the satisfaction of a performance condition and/or service condition. In addition, the Company issues common stock to participating employees pursuant to an employee stock purchase plan, and also issues common stock awards and deferred restricted stock units to members of its board of directors in accordance with its board of director compensation program. The following table reflects the total stock-based compensation expense (continuing and discontinued operations) recorded during the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ 2023 2022 2023 2022 Restricted stock units ​ $ 3,604 ​ $ 3,178 ​ $ 8,997 ​ $ 18,433 Employee stock purchase plan ​ 391 ​ 307 ​ 1,094 ​ 1,600 Total stock-based compensation expense for continuing and discontinued operations ​ $ 3,995 ​ $ 3,485 ​ $ 10,091 ​ $ 20,033 ​ Restricted stock units granted with performance goals may also have a required service period following the achievement of all or a portion of the performance goals. The following table reflects restricted stock units and common stock awards granted during the nine months ended June 30, 2023 and 2022: ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended June 30, ​ 2023 2022 Time-based restricted stock units ​ 311,609 ​ 94,429 Common stock awards — 49,063 Performance-based restricted stock units 278,457 88,204 Total units 590,066 231,696 ​ Time-Based Restricted Stock Unit Grants Restricted stock units granted with a required service period typically have three-year vesting schedules in which one-third Certain members of the Board of Directors have elected to defer receiving their annual stock awards and related quarterly dividends, if any, until they attain a certain age or cease to provide services as a member of the Company’s Board of Directors. Annual deferred stock awards granted during fiscal years 2023 and 2022 were vested upon issuance. Performance-Based Restricted Stock Unit Grants Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Board of Directors. The criteria for performance-based awards are weighted and have threshold, target and maximum performance goals. Performance-based restricted stock unit awards granted in fiscal year 2023 and 2022 allow participants to earn 100% of the restricted stock units if the Company’s performance meets or exceeds its target goal for each applicable financial metric, up to a maximum of 200% if the Company’s performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals are measured over a three-year period for each year’s restricted stock unit awards and at the end of the period to determine the number of restricted stock units earned, if any, by recipients who continue to meet the service requirement. Upon the third anniversary of each year’s restricted stock unit awards’ grant date, the Company’s Board of Directors determines the number of restricted stock units earned for participants who continue to meet the service requirements on the vest date. Awards Granted to the Board of Directors The stock-based compensation granted to members of the Company’s Board of Directors includes common stock awards, restricted stock unit awards, and deferred common stock and restricted stock unit awards. Restricted Stock Unit Activity The following table summarizes restricted stock unit activity for the nine months ended June 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding as of September 30, 2022 538,238 ​ $ 71.99 Granted 590,066 ​ $ 55.10 Vested (263,777) ​ $ 55.76 Forfeited (104,220) ​ $ 73.62 Outstanding as of June 30, 2023 760,307 ​ $ 66.22 ​ The weighted average grant date fair value of restricted stock units granted during the three months ended June 30, 2023 and 2022 was $42.35 and $80.58, respectively. The fair value of restricted stock units vested during the three months ended June 30, 2023 and 2022 was $0.1 million and $0.2 million, respectively. The weighted average grant date fair value of restricted stock units granted during the nine months ended June 30, 2023 and 2022 was $55.10 and $103.00, respectively. For the three months ended June 30, 2023 and 2022, the Company remitted less than $0.1 million in each period collected from employees to satisfy their tax obligations as a result of share issuances. During the nine months ended June 30, 2023 and 2022, the Company remitted $4.9 million and $25.1 million, respectively, to satisfy employee tax obligations as a result of share issuances, of which $4.9 million and zero, respectively, was paid by the Company. As of June 30, 2023, the unrecognized stock-based compensation expense related to these stock awards that are expected to vest was $27.4 million and will be recognized over an estimated weighted average service period of 1.9 years. Employee Stock Purchase Plan The Company maintains an employee stock purchase plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s common stock at the beginning or the end of the semi-annual offering period, whichever is lower. There were 39,479 and 51,133 shares, respectively, purchased by employees under the employee stock purchase plan during the nine months ended June 30, 2023 and 2022.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	16. Fair Value Measurement Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured and recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheets as of June 30, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 589,326 ​ $ 589,326 ​ $ — ​ $ — Available-for-sale securities ​ 559,914 ​ 127,592 ​ ​ 432,322 ​ — Net investment hedge ​ 984 ​ — ​ 984 ​ — Total assets ​ $ 1,150,224 ​ $ 716,918 ​ $ 433,306 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 428 ​ ​ — ​ ​ 428 ​ ​ — Total liabilities ​ $ 428 ​ $ — ​ $ 428 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2022 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 374,804 ​ $ 374,055 ​ $ 749 ​ $ — Available-for-sale securities ​ 1,263,782 ​ 651,800 ​ 611,982 ​ — Foreign exchange contracts ​ 634 ​ — ​ 634 ​ — Net investment hedge ​ ​ 124,789 ​ ​ — ​ ​ 124,789 ​ ​ — Total assets ​ $ 1,764,009 ​ $ 1,025,855 ​ $ 738,154 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 230 ​ $ — ​ ​ 230 ​ ​ — Total liabilities ​ $ 230 ​ $ — ​ $ 230 ​ $ — ​ Cash Equivalents Cash equivalents consist of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. The Company considers all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents. The fair values of these investments approximate their carrying values. Available-For-Sale Securities Available-for-sale securities primarily consist of municipal securities and U.S. government-backed securities, and as such are classified as Level 1. Investments classified as Level 2 consist of debt securities that are valued using matrix pricing and benchmarking because they are not actively traded and bank certificates of deposit. Matrix pricing is a mathematical technique used to value securities by relying on the securities’ relationship to other benchmark quoted prices. Foreign Exchange Contracts Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts. Net Investment Hedge Net investment hedge assets are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts. Contingent Consideration Liability The contingent consideration liability related to acquisitions is measured and reported at fair value using the real options method based on the unobservable inputs that are significant to the fair value and classified with Level 3 of the fair value hierarchy. The amount is contingent based on the acquired business’ performance through September 30, 2023. Please refer to Note 4, Business Combinations Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis During the three and nine months ended June 30, 2023 and 2022, the Company did not record any material fair value measurements for assets or liabilities on a nonrecurring basis.

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	17. Income Taxes The Company recorded an income tax benefit of $1.2 million and $9.1 million, respectively during the three and nine months ended June 30, 2023. The tax benefit for the three months ended June 30, 2023 was primarily driven by the pre-tax loss from operations during the period. The tax benefit for the nine months ended June 30, 2023 was primarily driven by the pre-tax loss from operations and a $1.4 million deferred tax benefit resulting from the extension of a tax incentive in China. The effective tax rates for the three and nine months ended June 30, 2023 are slightly higher than statutory rates. The effective rates are driven higher than statutory rates by the discrete tax benefit in China noted above and the fair value adjustment of the contingent consideration related to the B Medical acquisition. The contingent consideration generated $18.5 million of pre-tax income that is not subject to income taxes, therefore, the tax benefit is being driven by a tax loss that is significantly higher than the book loss for these periods. The Company recorded an income tax provision of $7.3 million and benefit of $0.6 million, respectively, during the three and nine months ended June 30, 2022. The tax provision for the three months ended June 30, 2022 was primarily driven by a true-up of the effective tax rate on a year-to-date basis. These changes were the result of fluctuations in expected global income from operations. The tax benefit for the nine months ended June 30, 2022 was driven by the pre-tax loss and a $4.6 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense. The tax benefit for the nine months ended June 30, 2022 was partially offset by a $0.7 million charge to increase the deferred tax liability to reflect a change in the blended state income tax rate resulting from the sale of the semiconductor business. In the period ended June 30, 2022, the Company did not include the U.S. business in the computation of the estimated annual effective rate. We have utilized the discrete effective tax rate method, as allowed by U.S. GAAP, to calculate the interim income tax provision. The U.S. tax benefit was computed discretely on a year-to-date basis. The taxable loss from continuing operations in the United States would have driven significant volatility in the estimated annual effective tax rate. Considering the level of pre-tax income forecasted in the year, small changes in the forecast for the remainder of the year would change the estimated annual effective tax rate substantially. The Company concluded that calculating the tax provision for the United States discretely was a more appropriate reflection of the year-to-date tax provision as of June 30, 2022. The in the course of The Company maintains liabilities for unrecognized tax benefits. These liabilities involve judgment and estimation, and they are monitored based on the best information available. The Company recognizes interest related to unrecognized tax benefits as unrecognized benefits The In on those benefits will be reduced by in the next twelve months

Net (Loss) Income per Share

Net (Loss) Income per Share	9 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net (Loss) Income per Share	18. Net (Loss) Income per Share The calculations of basic and diluted net income (loss) per share and basic and diluted weighted average shares outstanding are as follows for the three and nine months ended June 30, 2023 and 2022 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ June 30, ​ June 30, ​ 2023 2022 2023 2022 Loss from continuing operations ​ $ (2,463) ​ $ (7,015) ​ $ (15,689) ​ $ (5,973) Income (loss) from discontinued operations, net of tax ​ 993 ​ (2,555) ​ (1,943) ​ 2,159,597 Net (loss) income ​ $ (1,470) ​ $ (9,570) ​ $ (17,632) ​ $ 2,153,624 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic and diluted (loss) income per share ​ 63,432 ​ 74,989 ​ 68,494 ​ 74,879 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted net (loss) income per share: ​ ​ ​ ​ Loss from continuing operations ​ $ (0.04) ​ $ (0.09) ​ $ (0.23) ​ $ (0.08) Income (loss) from discontinued operations, net of tax ​ 0.02 ​ (0.03) ​ (0.03) ​ 28.84 Net (loss) income per share ​ $ (0.02) ​ $ (0.13) ​ $ (0.26) ​ $ 28.76 ​ During the nine months ended June 30, 2023 and 2022, restricted stock units of 334,467 and 59,513, respectively, were excluded from the computation of diluted loss per share as their effect would be antidilutive to earnings per share for continuing operations based on the treasury stock method.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Jun. 30, 2023
Segment and Geographic Information
Segment and Geographic Information	19. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company operates in two reportable segments, the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments. The Company previously operated in three reportable segments, the Semiconductor Solutions Group segment, the Life Sciences Products segment, and the Life Sciences Services segment. The Company’s Life Sciences Products segment provides automated cold storage solutions for biological and chemical compound samples. The Company’s storage systems provide reliable automation and sample inventory management at temperatures down to -190°C and can store anywhere from one to millions of samples. The Company’s sample management solutions include consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. This portfolio provides customers with the highest level of sample quality, security, availability, intelligence, and integrity throughout the lifecycle of samples providing customers with complete end-to-end cold chain of custody capabilities. The Company also provides controlled rate thawing devices for customers in the medical, biotechnology and pharmaceutical industries. The Company’s Life Sciences Services business is a leading provider of solutions addressing the many needs of customers in genomic analysis and the management and care of biological samples used in pharmaceutical, biotechnology, healthcare, clinical, and academic research and development markets. The Company processes millions of samples every year, each containing valuable information that must be delivered or preserved with the sample. The Company’s genomic services provide a broad capability to customers for sequencing and synthesis of genes. The Company’s sample management services include off-site storage, transport, and laboratory services, as well as interactive informatics solutions. The storage services include short- and long-term sample storage and management of the cold chain of custody from collection, to storage, to retrieving the sample which ultimately may go back into the research workflow. Management considers adjusted operating income, which excludes charges related to amortization of completed technology, purchase accounting impacts on inventory, amortization of other intangible assets, restructuring charges, contingent consideration fair value adjustments, tariff adjustments, and other unallocated corporate expenses, as the primary performance metric when evaluating the Company’s operations. The following is the summary of the financial information for the Company’s reportable segments for the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 Revenue: ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 74,571 ​ $ 47,369 ​ $ 223,091 ​ $ 150,861 Life Sciences Services ​ ​ 91,377 ​ 85,366 ​ 269,624 ​ 267,070 Total revenue ​ ​ $ 165,948 ​ $ 132,735 ​ $ 492,715 ​ $ 417,931 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income / (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ (4,878) ​ $ 1,965 ​ $ (25,077) ​ $ 11,173 Life Sciences Services ​ ​ (3,813) ​ 697 ​ (13,302) ​ 10,759 Segment operating (loss) income ​ ​ ​ (8,691) ​ ​ 2,662 ​ ​ (38,379) ​ ​ 21,932 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of completed technology ​ ​ ​ 4,656 ​ ​ 1,810 ​ ​ 13,725 ​ ​ 5,424 Purchase accounting impact on inventory ​ ​ ​ 2,956 ​ ​ — ​ ​ 8,737 ​ ​ — Amortization of other intangible assets ​ ​ ​ 7,522 ​ ​ 5,745 ​ ​ 22,403 ​ ​ 18,064 Restructuring charges ​ ​ ​ 812 ​ ​ 25 ​ ​ 3,773 ​ ​ 319 Contingent consideration - fair value adjustments ​ ​ ​ (1,404) ​ ​ — ​ ​ (18,549) ​ ​ — Tariff adjustment ​ ​ ​ — ​ ​ — ​ ​ — ​ ​ (486) Other unallocated corporate expenses ​ ​ ​ (7,397) ​ ​ 155 ​ ​ (11,970) ​ ​ 8,717 Total operating (loss) income ​ ​ ​ (15,836) ​ ​ (5,073) ​ ​ (56,498) ​ ​ (10,106) Interest income ​ ​ ​ 11,347 ​ ​ 6,822 ​ ​ 32,406 ​ ​ 9,933 Interest expense ​ ​ ​ — ​ ​ (2,101) ​ ​ — ​ ​ (4,111) Loss on extinguishment of debt ​ ​ ​ — ​ ​ — ​ ​ — ​ ​ (632) Other, net ​ ​ ​ 819 ​ ​ 630 ​ ​ (704) ​ ​ (1,617) (Loss) income before income taxes ​ ​ $ (3,670) ​ $ 278 ​ $ (24,796) ​ $ (6,533) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ June 30, 2023 ​ September 30, 2022 ​ ​ ​ Life Sciences Products ​ ​ ​ ​ ​ $ 948,701 ​ $ 378,790 ​ ​ ​ Life Sciences Services ​ ​ ​ ​ ​ ​ 824,018 ​ ​ 849,603 ​ ​ ​ Total assets ​ ​ ​ ​ ​ $ 1,772,719 ​ $ 1,228,393 ​ ​ ​ ​ ​ The following is a reconciliation of the segment assets to the corresponding amounts presented in the Condensed Consolidated Balance Sheets as of June 30, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ June 30, September 30, ​ ​ 2023 ​ 2022 Segment assets $ 1,772,719 $ 1,228,393 Cash and cash equivalents, restricted cash, and marketable securities ​ 1,296,074 ​ 2,305,081 Deferred tax assets ​ — ​ 1,169 Other assets ​ ​ 623 ​ ​ 181,479 Total assets ​ $ 3,069,416 ​ $ 3,716,122 ​ ​ Revenue from external customers is attributed to geographic areas based on locations in which customer orders are placed. Net revenue by geographic area for the three and nine months ended June 30, 2023 and 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ 2023 ​ 2022 ​ 2023 ​ 2022 Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ $ 91,018 ​ $ 88,380 ​ $ 267,437 ​ $ 272,750 Rest of Europe ​ ​ 23,594 ​ ​ 17,148 ​ ​ 84,448 ​ ​ 57,177 Africa ​ ​ 19,064 ​ ​ 86 ​ ​ 44,901 ​ ​ 1,305 China ​ ​ 12,766 ​ ​ 12,906 ​ ​ 38,153 ​ ​ 39,704 Asia Pacific/ Other ​ ​ 10,700 ​ ​ 6,114 ​ ​ 37,767 ​ ​ 23,780 United Kingdom ​ ​ 8,806 ​ ​ 8,101 ​ ​ 20,009 ​ ​ 23,215 Total revenue ​ $ 165,948 ​ $ 132,735 ​ $ 492,715 ​ $ 417,931 ​ ​ Revenue for the United States comprises 99% of the revenue for North America for each of the three and nine months ended June 30, 2023 and 2022. Significant Customers The Company had one individual customer that accounted for 10% or more of its consolidated revenue for the three months ended June 30, 2023 and no individual customer that accounted for 10% or more of its consolidated revenue for the three months ended June 30, 2022. The Company had one individual customer that accounted for 10% or more of its consolidated revenue for nine months ended June 30, 2023 and no individual customer that accounted for 10% or more of its consolidated revenue for the nine months ended June 30, 2022. This customer is the same for each of the fiscal 2023 periods and is related to the Life Science Products segment and is a distributor shipping to end users in approximately 30 countries. There were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of June 30, 2023 and September 30, 2022.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	20. Commitments and Contingencies Tariff Matter With the assistance of a third-party consultant, during the first quarter of fiscal year 2021 the Company initiated a review of the transaction value it used to calculate tariffs on inter-company imports of samples shipped from its GENEWIZ business. As a result, this review and a new interpretation surrounding the valuation method used to calculate the estimated transaction value, the Company revised its estimate of the tariffs owed and recorded a liability of $6.1 million in the second quarter of fiscal 2021. The Company submitted a payment in the amount of $5.9 million to the customs authorities during fiscal 2022, related to November 2021 and prior periods. The customs authorities will review the Company’s calculation of tariffs for these periods and determine if any further tariffs are owed. The Company does not expect to incur any significant penalties associated with the tariffs. Purchase Commitments As of June 30, 2023, the Company had non-cancellable commitments of $70.8 million, comprised of purchase orders for inventory of $48.1 million and information technology related commitments of $22.7 million. Contingencies The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or, in certain instances, provide reasonable ranges of potential losses. The Company may also have certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards Vacuum LLC (a member of the Atlas Copco Group) in connection with the Company’s sale of its semiconductor cryogenics business in the fourth quarter of fiscal year 2018. In the third quarter of fiscal year 2020, Edwards asserted claims for indemnification under the definitive agreement relating to alleged breaches of representations and warranties relating to customer warranty claims and inventory (the “2020 Claim”). In addition, in January 2023, Edwards filed a lawsuit against the Company in the Supreme Court of the State of New York in the County of New York seeking indemnification from the Company under such definitive agreement for $1.0 million and other related damages, including interest and attorney’s fees, arising from a third-party claim that was included as part of their initial claims (the “2023 Claim”). In the second quarter of fiscal 2023, the Company accrued a liability of $2.5 million for the litigation with Edwards related to the 2020 and 2023 Claim of which $0.8 million was paid during the third quarter of 2023. In April 2023, the Company responded to and filed a counterclaim against Edwards for the 2023 Claim alleging breach of the definitive agreements by Edwards and seeking a declaratory judgment. During the third quarter of fiscal 2023, the Company and Edwards entered into a settlement agreement related to the 2023 Claim to avoid the costs and uncertainties of potential litigation. Under the settlement agreement, the Company paid Edwards $0.8 million from one of the indemnification escrows established at closing of the sale in return for the release of the 2023 Claim and any residual funds in this escrow. The 2020 Claim remains outstanding and $1.7 million remains in the balance of the accrued liability. The Company cannot determine the probability of any losses or outcome of the 2020 Claim including the amount of any indemnifiable losses, if any, resulting from these claims. However, the Company does not believe that this claim will have a material adverse effect on its consolidated financial position or results of operations. If the resolution of the 2020 Claim results in indemnifiable losses in excess of the applicable indemnification deductibles established under the definitive agreement, Edwards would be required to seek recovery under the representation and warranty insurance Edwards obtained in connection with the closing of the sale of the semiconductor cryogenics business. Management believes that any indemnifiable losses in excess of the applicable deductibles established in the definitive agreement would be covered by such insurance. For indemnifiable claims other than those arising from breaches of representations and warranties and for indemnifiable claims arising from breaches of representations and warranties exceeding the maximum coverage of the representations and warranties insurance policy, Edwards could seek recovery of such indemnifiable losses, if any, directly from the Company. In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be no assurance that the Company’s assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company’s consolidated financial position or results of operations in particular quarterly or annual periods.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Event As part of the $1.5 billion share repurchase authorization, the Company entered into open market repurchase arrangements in March 2023 for the repurchase of up to $500.0 million of its common stock subject to market and business conditions, legal requirements, and other factors. The Company received settlement of 2.0 million shares of common stock for $91.6 million (excluding fees, commissions, and excise tax) under these arrangements subsequent to June 30, 2023 and as of the filing of this Quarterly Report on Form 10-Q.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and all entities where it has a controlling financial interest and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying year-end balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023, and the results of its operations for the three and nine months ended June 30, 2023 and 2022, and cash flows for the nine months ended June 30, 2023 and 2022, respectively. Certain information and disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022 filed with the U.S. Securities and Exchange Commission on November 25, 2022 (the “2022 Annual Report on Form 10-K”).
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect amounts reported in the financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, contingent consideration liabilities related to business combinations, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition, will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 in the analysis of its financial statements.
Business Combinations	Business Combinations The Company accounts for business acquisitions using the purchase method of accounting, in accordance with which assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. The fair value of the consideration paid, including contingent consideration, is assigned to the assets acquired and liabilities assumed based on their respective fair values. Goodwill represents the excess of the purchase price over the estimated fair values of the assets acquired and liabilities assumed. Significant judgment is used in determining fair values of assets acquired and liabilities assumed and contingent consideration, as well as intangibles and their estimated useful lives. Fair value and useful life determinations may be based on, among other factors, estimates of future expected cash flows and appropriate discount rates used in computing present values. These judgments may materially impact the estimates used in allocating acquisition date fair values to assets acquired and liabilities assumed, as well as our current and future operating results. Actual results may vary from these estimates and may result in adjustments to goodwill and acquisition date fair values of assets and liabilities during a measurement period or upon a final determination of asset and liability fair values, whichever occurs first. Adjustments to fair values of assets and liabilities made after the end of the measurement period are recorded within our operating results. Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled.
Foreign Currency Translation	Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expense)” in the Condensed Consolidated Statements of Operations. Net foreign currency transaction and remeasurement gains were $0.1 million and $0.3 million for the three months ended June 30, 2023 and 2022, respectively. Net foreign currency transaction and remeasurement losses were $2.7 million and $2.9 million during the nine months ended June 30, 2023 and 2022, respectively. The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets and presented as “Foreign currency translation adjustments” in the Condensed Consolidated Statements of Comprehensive Income (Loss).
Derivative Financial Instruments	Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expense)” in the Condensed Consolidated Statements of Operations and are as follows for the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ June 30, ​ June 30, ​ 2023 2022 2023 2022 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ 182 ​ $ 848 ​ $ (1,930) ​ $ 1,903 ​ The fair values of the forward contracts are recorded in the Condensed Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts.
Hedging Activities	Hedging Activities On February 1, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $1.0 billion for €915.0 million at a weighted average interest rate of 1.20% . The designated notional amount was $960.0 million and the actual interest rate was 1.28% . The 1.28% rate was in the range of the market value for that day and was the true interest rate on the notional amount. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries requiring an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap on February 1, 2023, the Company delivered a notional amount of €852.0 million and received a notional amount of $960.0 million at an exchange rate of 1.13 , which included realization of a gain of $29.3 million, which was recorded in “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. On February 1, 2023, the Company entered into another cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $436.0 million for €400.0 million at a weighted average interest rate of 1.66%. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on February 1, 2024. The cross-currency swaps are marked to market at each reporting period, representing the fair values of the cross-currency swap and any changes in fair value are recognized as a component of “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. Interest accrued on the cross-currency swap is recorded within “Interest income” in the Condensed Consolidated Statements of Operations. For the three and nine months ended June 30, 2023, the Company recorded a net loss of $0.2 and $70.5 million, respectively, to “Accumulated other comprehensive income (loss)” and recorded “Interest income” of $1.8 million and $7.1 million on these instruments for the three and nine months ended June 30, 2023, respectively.
Market Securities	Marketable Securities The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the Condensed Consolidated Balance Sheets. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. Unrealized gains and losses are excluded from earnings and reported as a separate component of “Accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets until the security is sold or matures. Gains or losses realized from sales of marketable securities are computed based on the specific identification method and recognized as a component of “Other income (expense)” in the accompanying unaudited Condensed Consolidated Statements of Operations. The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value. The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term prospects of the issuer, the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of its amortized cost basis. If the Company believes that an other-than-temporary decline in fair value has occurred, it writes down the investment to its fair value and recognizes the credit loss in earnings and the non-credit loss in accumulated other comprehensive income or loss.
Fair Value Measurement	Fair Value Measurement The Company measures certain financial assets and liabilities, including cash equivalents, available-for-sale securities, accounts receivable, accounts payable, contingent consideration liability and derivative instruments at fair value. The Company applies a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following levels of inputs may be used to measure fair value: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible as of the reporting date. Active markets are those in which transactions for the asset and liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. The fair value hierarchy gives the highest priority to Level 1 inputs. ● Level 2: Observable inputs other than prices included in Level 1, including quoted prices for similar assets or liabilities in active markets and quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3: Unobservable inputs that are significant to the fair value of the assets or liabilities and reflect an entity’s own assumptions in pricing assets or liabilities since they are supported by little or no market activity. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, as well as considering counterparty credit risk in its assessment of fair value. The Company measures certain assets, including the cost and equity method investments, at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparable prices, and discounted cash flow projections. An impairment charge is recorded when the cost of the investment exceeds its fair value and this condition is determined to be other-than-temporary
Accounts Receivable and Allowance for Expected Credit Losses and Sales Returns	Accounts Receivable and Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on several factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Condensed Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in “Revenue” in the Condensed Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers.
Leases	Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the Condensed Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the Condensed Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the Condensed Consolidated Balance Sheets.
Goodwill	Goodwill Goodwill represents the excess of purchase price over the fair value of net tangible and identifiable intangible assets of businesses acquired by the Company. Goodwill is tested for impairment annually or more often if impairment indicators are present at the reporting unit level. The Company elected April 1 st Application of the goodwill impairment test requires significant judgment based on market and operational conditions at the time of the evaluation, including management’s best estimate of future business activity and the related estimates of future cash flows from the reporting units that include the associated goodwill. These periodic evaluations could cause management to conclude that impairment factors exist, requiring an adjustment of these assets to their then current fair market values. Future business conditions and/or activity could differ materially from the projections made by management which could result in impairment charges. The goodwill impairment test is performed at the reporting unit level. A reporting unit is either an operating segment or one level below it, which is referred to as a “component”. The level at which the impairment test is performed requires an assessment of whether the operations below an operating segment constitute a self-sustaining business, in which case testing is generally performed at this level. T he Company first assesses qualitative factors to determine whether the existence of events or circumstances indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines, based on this assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying value, management performs a quantitative goodwill impairment test by comparing the reporting unit’s fair value with its carrying value. An impairment loss is recognized for the amount by which the reporting unit’s carrying value exceeds its fair value, up to the total amount of goodwill allocated to the reporting unit. We determine fair values of our reporting units based on an income approach in accordance with the discounted cash flow method, (the “DCF Method”). The DCF Method is based on projected future cash flows and terminal value estimates discounted to their present values. Terminal value represents the present value an investor would pay on the valuation date for the rights to the cash flows of the business for the years subsequent to the discrete cash flow projection period. We consider the DCF Method to be the most appropriate valuation technique since it is based on management’s long-term financial projections. In addition to determining the fair value of our reporting units based on the DCF Method, we also compare the aggregate values of our net corporate assets and reporting unit fair values to our overall market capitalization and use certain market-based valuation techniques to assess the reasonableness of the reporting unit fair values determined in accordance with the DCF Method. The key inputs used in the DCF Method include revenue growth rates, gross margin percentages, selling, general and administrative expense percentages and discount rates that are at or above our weighted average cost of capital. We derive discount rates that are commensurate with the risks and uncertainties inherent in the respective reporting units and our internally developed projections of future cash flows. Application of the goodwill impairment test requires judgment based on market and operational conditions at the time of the evaluation, including management’s best estimates of the reporting unit’s future business activity and the related estimates and assumptions of future cash flows from the assets that include the associated goodwill. Different assumptions of revenue growth rates, gross margin percentages, selling, general and administrative expense percentages and the discount rate used in the DCF Method could result in different estimates of the reporting unit’s fair value as of each testing date.
Warranty Obligations	Warranty Obligations The Company establishes reserves for estimated costs of product warranties based on historical information. Product warranty reserves are recorded at the time product revenue is recognized, and retrofit accruals are recorded at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company.
Stock-Based Compensation	Stock-Based Compensation The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant. For awards that vest based on service conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period. For awards that vest subject to performance conditions, the Company recognizes stock-based compensation expense ratably over the performance period if it is probable that performance condition will be met and adjusts for the percentage of shares probable of achieving the performance goals. Each quarter, management assesses the probability of achieving the performance goals. The Company makes estimates of stock award forfeitures and the number of awards expected to vest. The Company considers many factors in developing forfeiture estimates, including award types, employee classes and historical experience. Current estimates may differ from actual results and future changes in estimates.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. The ASUs provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (“LIBOR”) and other interbank offered rates to alternative reference rates. The provisions of the ASUs were only available until December 31, 2022, when the reference rate replacement activity was expected to be completed. Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in the annual consolidated financial statements for fiscal 2023. In June 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)
Other	Other For further information regarding the Company’s significant accounting policies, please refer to Note 2, Summary of Significant Accounting Policies

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of realized gains (losses) on derivatives not designated as hedging instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ June 30, ​ June 30, ​ 2023 2022 2023 2022 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ 182 ​ $ 848 ​ $ (1,930) ​ $ 1,903

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ ​ Nine Months Ended June 30, ​ ​ 2022 ​ 2022 Revenue ​ ​ ​ ​ ​ Products ​ $ - ​ $ 244,962 Services ​ ​ - ​ ​ 19,468 Total revenue ​ ​ - ​ ​ 264,430 Cost of revenue ​ ​ ​ ​ ​ ​ Products ​ ​ - ​ ​ 141,165 Services ​ ​ - ​ ​ 11,159 Total cost of revenue ​ ​ - ​ ​ 152,324 Gross profit ​ ​ - ​ ​ 112,106 Operating expenses ​ ​ ​ ​ ​ ​ Research and development ​ ​ - ​ ​ 18,486 Selling, general and administrative ​ ​ 480 ​ ​ 30,622 Total operating expenses ​ ​ 480 ​ ​ 49,108 Operating (loss) income ​ ​ (480) ​ ​ 62,998 (Loss) gain on divestiture ​ ​ (990) ​ ​ 2,560,384 (Loss) income before income taxes ​ ​ (1,470) ​ ​ 2,623,382 Income tax provision ​ ​ 1,085 ​ ​ 463,785 Net (loss) income from discontinued operations ​ $ (2,555) ​ $ 2,159,597 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ 2022 ​ ​ 2022 Capital expenditures ​ $ - ​ $ 2,862 Stock-based compensation ​ $ - ​ $ 8,032 ​ ​ ​ ​ ​

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Jun. 30, 2023
Business Acquisition [Line Items]
Amounts of Assets and Liabilities at Fair Value as of Acquisition Date	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Accounts receivable ​ $ 19,549 Inventory ​ 49,497 Other assets ​ 10,769 Property plant and equipment ​ 54,149 Identifiable Intangible Assets: ​ ​ Completed technology ​ 100,600 Trademarks ​ 5,500 Customer relationships ​ 36,700 Backlog ​ 600 Other liabilities ​ (31,489) Deferred income taxes, net ​ ​ (42,974) Goodwill ​ ​ 229,260 Total purchase price, net of cash acquired ​ $ 432,160
Pro Forma Information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 165,948 ​ $ 152,641 ​ $ 492,715 ​ $ 510,074 Net (loss) income ​ $ 492 ​ $ (14,605) ​ $ (8,128) ​ $ 2,135,512
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition [Line Items]
Schedule of condensed consolidated results from B Medical	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ 2023 ​ 2023 ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 27,275 ​ $ 84,552 Net (loss) income ​ $ (5,169) ​ $ (18,174)

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost and Fair Value, Including Accrued Interest Receivable and Unrealized Holding Gains (Losses) on Short-term and Long-term Marketable Securities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value June 30, 2023: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 311,618 ​ $ (3,731) ​ $ 1 $ 307,888 Bank certificates of deposits ​ ​ 9,078 ​ ​ (194) ​ ​ — ​ ​ 8,884 Corporate securities ​ ​ 248,309 ​ ​ (5,186) ​ ​ — ​ ​ 243,123 Municipal securities ​ 20 ​ ​ (1) ​ ​ — ​ 19 ​ ​ $ 569,025 ​ $ (9,112) ​ $ 1 ​ $ 559,914 September 30, 2022: ​ ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies ​ $ 804,774 $ (6,163) $ 21 ​ $ 798,632 Bank certificates of deposits ​ ​ 8,335 ​ ​ (158) ​ ​ 1 ​ ​ 8,178 Corporate securities ​ ​ 406,270 ​ ​ (8,113) ​ ​ — ​ ​ 398,157 Municipal securities ​ 59,043 ​ ​ (226) ​ ​ — ​ 58,817 ​ ​ $ 1,278,422 ​ $ (14,660) ​ $ 22 ​ $ 1,263,784
Fair Value of Marketable Securities by Contractual Maturity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ $ 394,811 ​ $ 390,492 Due after one year through five years ​ 171,049 ​ 166,257 Due after five years through ten years ​ ​ — ​ ​ — Due after ten years ​ 3,165 ​ 3,165 Total marketable securities ​ $ 569,025 ​ $ 559,914

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	9 Months Ended
	Jun. 30, 2023
Presentation of Financial Statements [Abstract]
Summary of Accounts Receivable	The following is a summary of accounts receivable, net as of June 30, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ September 30, ​ 2023 2022 Accounts receivable ​ $ 171,422 ​ $ 168,920 Less allowance for expected credit losses ​ (8,403) ​ (5,162) Accounts receivable, net ​ $ 163,019 ​ $ 163,758
Allowance for Doubtful Accounts Activity	The allowance for expected credit losses for the nine months ended June 30, 2023 and fiscal year ended September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended ​ Year ended ​ ​ June 30, 2023 ​ September 30, 2022 ​ ​ ​ ​ ​ ​ ​ Balance at Beginning of Period ​ $ 5,162 ​ $ 4,318 Provisions ​ 6,963 ​ 3,536 Reversals of Bad Debt Expense ​ ​ (3,652) ​ ​ (2,278) Write-offs and Adjustments ​ (70) ​ ​ (414) Balance at End of Period ​ $ 8,403 ​ $ 5,162

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Summary of Inventories	The following is a summary of inventories at June 30, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ June 30, September 30, ​ 2023 2022 ​ ​ Raw materials and purchased parts $ 65,380 $ 39,685 Work-in-process ​ 8,088 ​ 4,816 Finished goods ​ 68,634 ​ 41,043 Total inventories $ 142,102 $ 85,544

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Components of goodwill by business segment	The changes in the Company’s goodwill by reportable segment for the nine months ended June 30, 2023 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance - September 30, 2022 ​ $ 154,612 ​ $ 359,011 ​ $ 513,623 Acquisitions ​ 229,260 ​ — ​ 229,260 Currency translation adjustments ​ ​ 50,655 ​ ​ 85 ​ ​ 50,740 Balance - June 30, 2023 ​ $ 434,527 ​ $ 359,096 ​ $ 793,623
Schedule of intangible assets	The components of the Company’s identifiable intangible assets as of June 30, 2023 and September 30, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ September 30, 2022 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 8,996 ​ $ 8,928 ​ $ 68 ​ $ 1,225 ​ $ 1,106 ​ $ 119 Completed technology ​ 252,424 ​ 84,206 ​ 168,218 ​ 99,525 ​ 37,991 ​ 61,534 Trademarks and trade names ​ 8,909 ​ 3,173 ​ 5,736 ​ 400 ​ 41 ​ 359 Non-competition agreements ​ ​ 731 ​ ​ 586 ​ ​ 145 ​ ​ 681 ​ ​ 439 ​ ​ 242 Customer relationships ​ 321,155 ​ 183,943 ​ 137,212 ​ 246,949 ​ 130,802 ​ 116,147 Other intangibles ​ ​ 904 ​ ​ 228 ​ ​ 676 ​ ​ 202 ​ ​ 202 ​ ​ — Total ​ $ 593,119 ​ $ 281,064 ​ $ 312,055 ​ $ 348,982 ​ $ 170,581 ​ $ 178,401
Schedule of future amortization expense	Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2023 the subsequent five fiscal years and thereafter is as follows (in thousands): ​ ​ ​ ​ 2023 ​ $ 11,366 2024 ​ 50,664 2025 ​ 49,292 2026 ​ 45,908 2027 ​ ​ 37,706 2028 ​ ​ 31,219 Thereafter ​ ​ 85,900 Total ​ $ 312,055

Warranty and Retrofit Costs (Ta

Warranty and Retrofit Costs (Tables)	9 Months Ended
	Jun. 30, 2023
Product Warranties Disclosures [Abstract]
Product Warranty and Retrofit Activity on Gross Basis	The following is a summary of product warranty and retrofit activity for the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at Beginning of Period ​ $ 5,380 ​ $ 2,491 ​ $ 2,890 ​ $ 2,330 ​ Adjustment for Acquisitions ​ ​ — ​ ​ — ​ ​ 2,303 ​ ​ — ​ Accruals ​ ​ 2,407 ​ ​ 663 ​ ​ 3,936 ​ ​ 1,875 ​ Cost Incurred ​ ​ (1,529) ​ ​ (630) ​ ​ (2,871) ​ ​ (1,681) ​ Balance at End of Period ​ $ 6,258 ​ $ 2,524 ​ $ 6,258 ​ $ 2,524

Leases (Tables)

Leases (Tables)	9 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of leases	The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ $ 3,332 ​ $ 2,468 ​ $ 9,450 ​ $ 7,028 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ 183 ​ ​ 18 ​ ​ 409 ​ ​ 147 ​ Interest on lease liabilities ​ ​ 12 ​ ​ - ​ ​ 26 ​ ​ 5 ​ Total finance lease costs ​ ​ 195 ​ ​ 18 ​ ​ 435 ​ ​ 152 ​ Total operating and finance lease costs ​ ​ 3,527 ​ ​ 2,486 ​ ​ 9,885 ​ ​ 7,180 ​ Variable lease costs ​ ​ 752 ​ ​ 783 ​ ​ 2,764 ​ ​ 2,056 ​ Short-term lease costs ​ ​ 415 ​ ​ 640 ​ ​ 1,009 ​ ​ 1,357 ​ Sublease income ​ ​ (2) ​ ​ - ​ ​ (6) ​ ​ - ​ Total lease costs ​ $ 4,692 ​ $ 3,909 ​ $ 13,652 ​ $ 10,593 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ September 30, 2022 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ ​ ​ ​ $ 67,352 ​ $ 54,059 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ $ 8,675 ​ $ 6,924 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ 61,799 ​ ​ 49,227 ​ Total operating lease liabilities ​ ​ ​ ​ ​ ​ ​ $ 70,474 ​ $ 56,151 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ ​ ​ ​ $ 4,511 ​ $ 2,476 ​ Accumulated amortization ​ ​ ​ ​ ​ ​ ​ ​ (2,501) ​ ​ (2,276) ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ $ 2,010 ​ $ 200 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ $ 673 ​ $ 96 ​ Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ 1,467 ​ ​ 98 ​ Total finance lease liabilities ​ ​ ​ ​ ​ ​ ​ $ 2,140 ​ $ 194 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ 11.22 ​ ​ 10.82 ​ Finance leases ​ ​ ​ ​ ​ ​ ​ ​ 3.54 ​ ​ 2.19 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ 4.21 % ​ 3.93 % Finance leases ​ ​ ​ ​ ​ ​ ​ ​ 2.50 % ​ 1.29 % ​ Supplemental cash flow information related to leases was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows - operating leases ​ $ 2,947 ​ $ 2,116 ​ $ 7,895 ​ $ 5,715 ​ Operating cash flows - finance leases ​ $ 12 ​ $ - ​ $ 26 ​ $ 4 ​ Financing cash flows - finance leases ​ $ 169 ​ $ 43 ​ $ 377 ​ $ 360 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 6,585 ​ $ 122 ​ $ 13,021 ​ $ 7,612 ​ Finance leases ​ $ 576 ​ $ - ​ $ 1,672 ​ $ - ​
Schedule of future lease payments of operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases Operating Leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ $ 190 ​ $ 2,937 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ 711 ​ ​ 11,107 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ 619 ​ ​ 10,797 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ 453 ​ ​ 8,311 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ 217 ​ ​ 7,875 ​ 2028 ​ ​ ​ ​ ​ ​ ​ ​ 38 ​ ​ 7,548 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ 9 ​ ​ 42,672 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ 2,237 ​ ​ 91,247 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ (97) ​ ​ (20,773) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ $ 2,140 ​ $ 70,474 ​ ​ ​ As of June 30, 2023, the Company had entered into leases that had not commenced with future lease payments of $9.3 million. These leases are not reflected in the ROU asset and lease liability in the Condensed Consolidated Balance Sheets. These leases commence in the fourth quarter of fiscal 2023.
Schedule of future lease payments of finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases Operating Leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ $ 190 ​ $ 2,937 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ 711 ​ ​ 11,107 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ 619 ​ ​ 10,797 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ 453 ​ ​ 8,311 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ 217 ​ ​ 7,875 ​ 2028 ​ ​ ​ ​ ​ ​ ​ ​ 38 ​ ​ 7,548 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ 9 ​ ​ 42,672 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ 2,237 ​ ​ 91,247 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ (97) ​ ​ (20,773) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ $ 2,140 ​ $ 70,474 ​ ​ ​ As of June 30, 2023, the Company had entered into leases that had not commenced with future lease payments of $9.3 million. These leases are not reflected in the ROU asset and lease liability in the Condensed Consolidated Balance Sheets. These leases commence in the fourth quarter of fiscal 2023.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue by Reporting Unit	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ ​ ​ ​ 2023 ​ 2022 ​ ​ 2023 ​ 2022 Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products, excluding B Medical ​ ​ ​ $ 47,810 ​ $ 47,369 ​ $ 139,386 ​ $ 150,861 B Medical ​ ​ ​ ​ 26,761 ​ ​ - ​ ​ 83,705 ​ ​ - Sample Repository Solutions ​ ​ ​ ​ 27,531 ​ ​ 26,000 ​ ​ 82,452 ​ ​ 78,806 Genomic Services ​ ​ ​ ​ 63,846 ​ ​ 59,366 ​ ​ 187,172 ​ ​ 188,264 Total revenue ​ ​ ​ $ 165,948 ​ $ 132,735 ​ $ 492,715 ​ $ 417,931
Remaining Performance Obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining performance obligations ​ $ 62,778 ​ $ 24,654 ​ $ 87,432

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jun. 30, 2023
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ 2023 2022 2023 2022 Restricted stock units ​ $ 3,604 ​ $ 3,178 ​ $ 8,997 ​ $ 18,433 Employee stock purchase plan ​ 391 ​ 307 ​ 1,094 ​ 1,600 Total stock-based compensation expense for continuing and discontinued operations ​ $ 3,995 ​ $ 3,485 ​ $ 10,091 ​ $ 20,033
Restricted Stock Unit Activity	​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended June 30, ​ 2023 2022 Time-based restricted stock units ​ 311,609 ​ 94,429 Common stock awards — 49,063 Performance-based restricted stock units 278,457 88,204 Total units 590,066 231,696 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding as of September 30, 2022 538,238 ​ $ 71.99 Granted 590,066 ​ $ 55.10 Vested (263,777) ​ $ 55.76 Forfeited (104,220) ​ $ 73.62 Outstanding as of June 30, 2023 760,307 ​ $ 66.22

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 589,326 ​ $ 589,326 ​ $ — ​ $ — Available-for-sale securities ​ 559,914 ​ 127,592 ​ ​ 432,322 ​ — Net investment hedge ​ 984 ​ — ​ 984 ​ — Total assets ​ $ 1,150,224 ​ $ 716,918 ​ $ 433,306 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 428 ​ ​ — ​ ​ 428 ​ ​ — Total liabilities ​ $ 428 ​ $ — ​ $ 428 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2022 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 374,804 ​ $ 374,055 ​ $ 749 ​ $ — Available-for-sale securities ​ 1,263,782 ​ 651,800 ​ 611,982 ​ — Foreign exchange contracts ​ 634 ​ — ​ 634 ​ — Net investment hedge ​ ​ 124,789 ​ ​ — ​ ​ 124,789 ​ ​ — Total assets ​ $ 1,764,009 ​ $ 1,025,855 ​ $ 738,154 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 230 ​ $ — ​ ​ 230 ​ ​ — Total liabilities ​ $ 230 ​ $ — ​ $ 230 ​ $ —

Net (Loss) Income per Share (Ta

Net (Loss) Income per Share (Tables)	9 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Reconciliation of Weighted Average Common Shares Outstanding for Purposes of Calculating Basic and Diluted Earnings Per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ June 30, ​ June 30, ​ 2023 2022 2023 2022 Loss from continuing operations ​ $ (2,463) ​ $ (7,015) ​ $ (15,689) ​ $ (5,973) Income (loss) from discontinued operations, net of tax ​ 993 ​ (2,555) ​ (1,943) ​ 2,159,597 Net (loss) income ​ $ (1,470) ​ $ (9,570) ​ $ (17,632) ​ $ 2,153,624 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic and diluted (loss) income per share ​ 63,432 ​ 74,989 ​ 68,494 ​ 74,879 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted net (loss) income per share: ​ ​ ​ ​ Loss from continuing operations ​ $ (0.04) ​ $ (0.09) ​ $ (0.23) ​ $ (0.08) Income (loss) from discontinued operations, net of tax ​ 0.02 ​ (0.03) ​ (0.03) ​ 28.84 Net (loss) income per share ​ $ (0.02) ​ $ (0.13) ​ $ (0.26) ​ $ 28.76

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Jun. 30, 2023
Segment and Geographic Information
Schedule of financial information for business segments	The following is the summary of the financial information for the Company’s reportable segments for the three and nine months ended June 30, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 Revenue: ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 74,571 ​ $ 47,369 ​ $ 223,091 ​ $ 150,861 Life Sciences Services ​ ​ 91,377 ​ 85,366 ​ 269,624 ​ 267,070 Total revenue ​ ​ $ 165,948 ​ $ 132,735 ​ $ 492,715 ​ $ 417,931 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income / (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ (4,878) ​ $ 1,965 ​ $ (25,077) ​ $ 11,173 Life Sciences Services ​ ​ (3,813) ​ 697 ​ (13,302) ​ 10,759 Segment operating (loss) income ​ ​ ​ (8,691) ​ ​ 2,662 ​ ​ (38,379) ​ ​ 21,932 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of completed technology ​ ​ ​ 4,656 ​ ​ 1,810 ​ ​ 13,725 ​ ​ 5,424 Purchase accounting impact on inventory ​ ​ ​ 2,956 ​ ​ — ​ ​ 8,737 ​ ​ — Amortization of other intangible assets ​ ​ ​ 7,522 ​ ​ 5,745 ​ ​ 22,403 ​ ​ 18,064 Restructuring charges ​ ​ ​ 812 ​ ​ 25 ​ ​ 3,773 ​ ​ 319 Contingent consideration - fair value adjustments ​ ​ ​ (1,404) ​ ​ — ​ ​ (18,549) ​ ​ — Tariff adjustment ​ ​ ​ — ​ ​ — ​ ​ — ​ ​ (486) Other unallocated corporate expenses ​ ​ ​ (7,397) ​ ​ 155 ​ ​ (11,970) ​ ​ 8,717 Total operating (loss) income ​ ​ ​ (15,836) ​ ​ (5,073) ​ ​ (56,498) ​ ​ (10,106) Interest income ​ ​ ​ 11,347 ​ ​ 6,822 ​ ​ 32,406 ​ ​ 9,933 Interest expense ​ ​ ​ — ​ ​ (2,101) ​ ​ — ​ ​ (4,111) Loss on extinguishment of debt ​ ​ ​ — ​ ​ — ​ ​ — ​ ​ (632) Other, net ​ ​ ​ 819 ​ ​ 630 ​ ​ (704) ​ ​ (1,617) (Loss) income before income taxes ​ ​ $ (3,670) ​ $ 278 ​ $ (24,796) ​ $ (6,533) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ June 30, 2023 ​ September 30, 2022 ​ ​ ​ Life Sciences Products ​ ​ ​ ​ ​ $ 948,701 ​ $ 378,790 ​ ​ ​ Life Sciences Services ​ ​ ​ ​ ​ ​ 824,018 ​ ​ 849,603 ​ ​ ​ Total assets ​ ​ ​ ​ ​ $ 1,772,719 ​ $ 1,228,393 ​ ​ ​
Schedule of reconciliation of reportable segment assets to corresponding consolidated amounts	The following is a reconciliation of the segment assets to the corresponding amounts presented in the Condensed Consolidated Balance Sheets as of June 30, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ June 30, September 30, ​ ​ 2023 ​ 2022 Segment assets $ 1,772,719 $ 1,228,393 Cash and cash equivalents, restricted cash, and marketable securities ​ 1,296,074 ​ 2,305,081 Deferred tax assets ​ — ​ 1,169 Other assets ​ ​ 623 ​ ​ 181,479 Total assets ​ $ 3,069,416 ​ $ 3,716,122
Schedule of revenue from external customers attributed to geographic areas	Revenue from external customers is attributed to geographic areas based on locations in which customer orders are placed. Net revenue by geographic area for the three and nine months ended June 30, 2023 and 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Nine Months Ended June 30, ​ 2023 ​ 2022 ​ 2023 ​ 2022 Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ $ 91,018 ​ $ 88,380 ​ $ 267,437 ​ $ 272,750 Rest of Europe ​ ​ 23,594 ​ ​ 17,148 ​ ​ 84,448 ​ ​ 57,177 Africa ​ ​ 19,064 ​ ​ 86 ​ ​ 44,901 ​ ​ 1,305 China ​ ​ 12,766 ​ ​ 12,906 ​ ​ 38,153 ​ ​ 39,704 Asia Pacific/ Other ​ ​ 10,700 ​ ​ 6,114 ​ ​ 37,767 ​ ​ 23,780 United Kingdom ​ ​ 8,806 ​ ​ 8,101 ​ ​ 20,009 ​ ​ 23,215 Total revenue ​ $ 165,948 ​ $ 132,735 ​ $ 492,715 ​ $ 417,931

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Foreign Currency Translation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Gain (Loss), Foreign Currency Transaction, before Tax [Abstract]
Foreign currency transaction and remeasurement gains (losses)	$ 0.1	$ 0.3	$ (2.7)	$ (2.9)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Derivative Financial Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [Abstract]
Realized gains (losses) on derivatives not designated as hedging instruments	$ 182	$ 848	$ (1,930)	$ 1,903

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Hedging Activities (Details) $ in Thousands, € in Millions		3 Months Ended		9 Months Ended
	Feb. 01, 2023 USD ($) $ / €	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Feb. 01, 2023 EUR (€) $ / €	Feb. 01, 2022 USD ($)	Feb. 01, 2022 EUR (€)
Derivative [Line Items]
Interest income		$ 11,347	$ 6,822	$ 32,406	$ 9,933
Currency Swap | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount, cross-currency swap, exchanged	$ 436,000						$ 1,000,000
Derivative, notional amount, cross-currency swap, received | €						€ 400		€ 915
Derivative, notional amount							$ 960,000
Derivative, fixed interest rate (as a percent)							1.28%	1.28%
Derivative, notional amount, cross-currency swap, maturity, deliver | €						€ 852
Derivative, notional amount, cross-currency swap, maturity, receive	$ 960,000
Derivative, forward exchange rate | $ / €	1.13					1.13
Gain on derivative	$ 29,300
Gain (loss) to accumulated other comprehensive income		(200)		(70,500)
Interest income		$ 1,800		$ 7,100
Currency Swap | Designated as Hedging Instrument | Weighted Average
Derivative [Line Items]
Derivative, variable interest rate	1.66%					1.66%	1.20%	1.20%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details) - Accounting Standards Update 2020-06	Jun. 30, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 01, 2022

Discontinued Operations - Gener

Discontinued Operations - General Information (Details) $ in Thousands		3 Months Ended	9 Months Ended	12 Months Ended
	Feb. 01, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2023 lease
Thomas H. Lee Partners, L.P.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transition service agreement, term, low end of range	3 months
Transition service agreement, term, high end of range	24 months
Sale leaseback transaction, lease agreements, number | lease					1
Lease agreements number of original Leases in effect | lease					2
Sale leaseback transaction, lease term	24 months
Sale leaseback transaction, termination notice period	90 days
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 2,900,000
(Loss) gain on divestiture		$ (990)	$ 2,560,384
Liability related to retention and stock compensation for former employees of the Company that were conveyed with the transaction	$ 18,100
Liability related to retention and stock compensation for former employees of the Company that were conveyed with the transaction, amount paid				$ 600

Discontinued Operations - Finan

Discontinued Operations - Financial Results (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net (loss) income from discontinued operations	$ 993	$ (2,555)	$ (1,943)	$ 2,159,597
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue				264,430
Total cost of revenue				152,324
Gross profit				112,106
Research and development				18,486
Selling, general and administrative		480		30,622
Total operating expenses		480		49,108
Operating (loss) income		(480)		62,998
(Loss) gain on divestiture		(990)		2,560,384
(Loss) income before income taxes		(1,470)		2,623,382
Income tax provision		1,085		463,785
Net (loss) income from discontinued operations	$ 1,000	$ (2,555)		2,159,597
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Products
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue				244,962
Total cost of revenue				141,165
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Services
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue				19,468
Total cost of revenue				$ 11,159

Discontinued Operations - Non-c

Discontinued Operations - Non-cash Items and Capital Expenditures (Details) - Discontinued Operations, Disposed of by Sale - Semiconductor Automation Business $ in Thousands	9 Months Ended
	Jun. 30, 2022 USD ($)
Discontinued Operation, Alternative Cash Flow Information [Abstract]
Capital expenditures	$ 2,862
Stock-based compensation	$ 8,032

Business Combinations - General

Business Combinations - General Information (Details) - country	Feb. 03, 2023	Oct. 03, 2022	Jul. 01, 2022
Ziath Ltd and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition	Feb. 02, 2023
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition		Oct. 03, 2022
B Medical Systems S.a.r.l and Subsidiaries | Minimum
Business Acquisition, Date of Acquisition [Abstract]
Number of countries in which entity operates		150
Barkey Holding GmbH and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition			Jul. 01, 2022

Business Combinations - Purchas

Business Combinations - Purchase Consideration (Details) $ in Thousands, € in Millions				9 Months Ended
	Feb. 03, 2023 USD ($)	Oct. 03, 2022 USD ($)	Jul. 01, 2022 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Oct. 03, 2022 EUR (€)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired				$ 386,508
Short-term restricted cash				2,287				$ 382,596
Contingent consideration liability				$ 0	$ 1,400	$ 18,500
Ziath Ltd and Subsidiaries
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired	$ 16,000
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition [Line Items]
Total purchase price		$ 432,200
Contingent consideration		17,000
Aggregate purchase price, net of cash acquired		$ 424,000
Additional contingent consideration | €							€ 50
Prepaid assets								43,100
Short-term restricted cash								$ 381,000
Contingent consideration liability, achievement of certain revenue targets, term		1 year
Contingent consideration liability					$ 1,400				$ 0
Barkey Holding GmbH and Subsidiaries
Business Acquisition [Line Items]
Total purchase price			$ 84,800

Business Combinations - Amounts

Business Combinations - Amounts of Assets and Liabilities at Fair Value as of Acquisition Date (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Feb. 03, 2023	Oct. 03, 2022	Sep. 30, 2022	Jul. 01, 2022
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 793,623			$ 513,623
Ziath Ltd and Subsidiaries
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Deferred income taxes, net		$ (1,100)
Goodwill		12,000
Ziath Ltd and Subsidiaries | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		4,100
Ziath Ltd and Subsidiaries | Trademarks
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		300
Ziath Ltd and Subsidiaries | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		$ 600
B Medical Systems S.a.r.l and Subsidiaries
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable			$ 19,549
Inventory			49,497
Other assets			10,769
Property, plant and equipment			54,149
Other liabilities			(31,489)
Deferred income taxes, net			(42,974)
Goodwill			229,260
Total purchase price, net of cash acquired			432,160
B Medical Systems S.a.r.l and Subsidiaries | Revision of Prior Period, Adjustment
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	400
Increase in accrued liabilities	$ 400
B Medical Systems S.a.r.l and Subsidiaries | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			100,600
B Medical Systems S.a.r.l and Subsidiaries | Trademarks
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			5,500
B Medical Systems S.a.r.l and Subsidiaries | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			36,700
B Medical Systems S.a.r.l and Subsidiaries | Order or Production Backlog
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			$ 600
Barkey Holding GmbH and Subsidiaries
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Deferred income taxes, net					$ (9,800)
Goodwill					57,800
Barkey Holding GmbH and Subsidiaries | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets					29,000
Barkey Holding GmbH and Subsidiaries | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets					$ 3,000

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired (Details)	Feb. 03, 2023	Oct. 03, 2022	Jul. 01, 2022
Ziath Ltd and Subsidiaries | Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	10 years
Ziath Ltd and Subsidiaries | Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	13 years
Ziath Ltd and Subsidiaries | Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	13 years
B Medical Systems S.a.r.l and Subsidiaries
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, valuation technique, discounted cash flow, measurement input, discount rate, percentage (as a percent)		13%
B Medical Systems S.a.r.l and Subsidiaries | Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		10 years
B Medical Systems S.a.r.l and Subsidiaries | Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		16 years
B Medical Systems S.a.r.l and Subsidiaries | Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		5 years
B Medical Systems S.a.r.l and Subsidiaries | Order or Production Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		1 year
Barkey Holding GmbH and Subsidiaries
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets			15 years

Business Combinations - Goodwil

Business Combinations - Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Feb. 03, 2023	Oct. 03, 2022	Sep. 30, 2022	Jul. 01, 2022
Business Combination, Goodwill [Abstract]
Goodwill	$ 793,623			$ 513,623
Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill	$ 434,527			$ 154,612
Ziath Ltd and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill		$ 12,000
Goodwill deductible for tax purposes		$ 0
B Medical Systems S.a.r.l and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill			$ 229,260
Goodwill deductible for tax purposes			0
B Medical Systems S.a.r.l and Subsidiaries | Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill			$ 229,300
Barkey Holding GmbH and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill					$ 57,800
Goodwill deductible for tax purposes					$ 0

Business Combinations - Results

Business Combinations - Results of Operations (Details) - B Medical Systems S.a.r.l and Subsidiaries - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2023
Business Acquisition, Pro Forma Information [Abstract]
Revenue	$ 27,275		$ 84,552
Net (loss) income	(5,169)		(18,174)
Acquisition related costs	$ 0	$ 3,600	$ 3,600

Business Combinations - Pro For

Business Combinations - Pro Forma Information - Tabular Disclosure (Details) - B Medical Systems S.a.r.l and Subsidiaries - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Acquisition, Pro Forma Information [Abstract]
Revenue	$ 165,948	$ 152,641	$ 492,715	$ 510,074
Net (loss) income	$ 492	$ (14,605)	$ (8,128)	$ 2,135,512

Business Combinations - Pro F_2

Business Combinations - Pro Forma Information - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Acquisition, Pro Forma Information [Abstract]
Business acquisition, pro forma information, purchase accounting adjustment, reversal of debt interest expense		$ 0.2
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition, Pro Forma Information [Abstract]
Business acquisition, pro forma information, purchase accounting adjustment, reversal of research and development expense capitalization		0		$ 1.4
Business acquisition, pro forma information, purchase accounting adjustment, property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense	$ 2	6.2	$ 5.9	18.9
Business acquisition, pro forma information, purchase accounting adjustment, transaction costs	$ 0	0	$ 3.6	8.9
Business acquisition, pro forma information, purchase accounting adjustment, reversal of debt interest expense				5.9
Business acquisition, pro forma information, purchase accounting adjustment, tax cost (benefit)		$ 1.6		$ 6.4

Marketable Securities - General

Marketable Securities - General Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Sales and maturities of marketable securities	$ 223,300	$ 499,800	$ 951,504	$ 503,505
Debt securities realized losses	$ 800		$ 800

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 569,025	$ 1,278,422
Gross Unrealized Losses	(9,112)	(14,660)
Gross Unrealized Gains	1	22
Fair Value	559,914	1,263,784
U.S. Treasury securities and obligations of U.S. government agencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	311,618	804,774
Gross Unrealized Losses	(3,731)	(6,163)
Gross Unrealized Gains	1	21
Fair Value	307,888	798,632
Bank certificates of deposits
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	9,078	8,335
Gross Unrealized Losses	(194)	(158)
Gross Unrealized Gains		1
Fair Value	8,884	8,178
Corporate securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	248,309	406,270
Gross Unrealized Losses	(5,186)	(8,113)
Fair Value	243,123	398,157
Municipal securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	20	59,043
Gross Unrealized Losses	(1)	(226)
Fair Value	$ 19	$ 58,817

Marketable Securities - Fair Va

Marketable Securities - Fair Value of Marketable Securities by Contractual Maturity (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
Amortized cost, due in one year or less, remainder of fiscal year	$ 394,811
Amortized cost, due in one year or less	0
Amortized cost, due after one year through five years	171,049
Amortized cost, due after ten years	3,165
Amortized cost	569,025
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Fair value, due in one year or less, remainder of fiscal year	390,492
Fair value, due in one year or less	0
Fair value, due after one year through five years	166,257
Fair value, due after ten years	3,165
Fair value	$ 559,914

Accounts Receivable, Net - Summ

Accounts Receivable, Net - Summary of Account Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable	$ 171,422	$ 168,920
Less allowance for expected credit losses	(8,403)	(5,162)
Accounts receivable, net	$ 163,019	$ 163,758

Accounts Receivable, Net - Allo

Accounts Receivable, Net - Allowance for Expected Credit Losses Activity (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Jun. 30, 2023	Sep. 30, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at beginning of period	$ 5,162	$ 4,318
Provisions	6,963	3,536
Reversals of bad debt expense	(3,652)	(2,278)
Write-offs and adjustments	(70)	(414)
Balance at end of period	$ 8,403	$ 5,162

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 65,380	$ 39,685
Work-in-process	8,088	4,816
Finished goods	68,634	41,043
Inventory, net	$ 142,102	$ 85,544

Inventories - Inventory Reserve

Inventories - Inventory Reserves (Details) - USD ($) $ in Millions	Jun. 30, 2023	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory Valuation Reserves	$ 4.3	$ 4.1

Capitalized Software Costs (Det

Capitalized Software Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2022
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 29.4		$ 29.4		$ 26.9
Capitalized computer software costs	0.7	$ 1.2	2.6	$ 2.8
Software Development
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 10.8		$ 10.8

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill Impairment Test (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Line Items]
Goodwill impairment	$ 0
Life Sciences Services
Goodwill [Line Items]
Goodwill impairment test, reporting unit, estimated fair value exceeded carrying value, percentage (as a percent)	24%
Life Sciences Products
Goodwill [Line Items]
Goodwill impairment test, reporting unit, estimated fair value exceeded carrying value, percentage (as a percent)	17%

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Goodwill Roll Forward - Tabular Disclosure (Details) $ in Thousands	9 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 513,623
Acquisitions	229,260
Currency translation adjustments	50,740
Goodwill, ending balance	793,623
Life Sciences Products
Goodwill [Roll Forward]
Goodwill, beginning balance	154,612
Acquisitions	229,260
Currency translation adjustments	50,655
Goodwill, ending balance	434,527
Life Sciences Services
Goodwill [Roll Forward]
Goodwill, beginning balance	359,011
Currency translation adjustments	85
Goodwill, ending balance	$ 359,096

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Goodwill Roll Forward - Additional Information (Details) $ in Thousands	9 Months Ended
	Jun. 30, 2023 USD ($)
Business Combination Segment Allocation [Line Items]
Acquisitions	$ 229,260
B Medical Systems S.a.r.l and Subsidiaries
Business Combination Segment Allocation [Line Items]
Acquisitions	$ 229,300

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Cost	$ 593,119	$ 348,982
Accumulated Amortization	281,064	170,581
Net Book Value	312,055	178,401
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	8,996	1,225
Accumulated Amortization	8,928	1,106
Net Book Value	68	119
Completed Technology
Finite-Lived Intangible Assets [Line Items]
Cost	252,424	99,525
Accumulated Amortization	84,206	37,991
Net Book Value	168,218	61,534
Trademarks and Trade Names
Finite-Lived Intangible Assets [Line Items]
Cost	8,909	400
Accumulated Amortization	3,173	41
Net Book Value	5,736	359
Noncompete Agreements
Finite-Lived Intangible Assets [Line Items]
Cost	731	681
Accumulated Amortization	586	439
Net Book Value	145	242
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Cost	321,155	246,949
Accumulated Amortization	183,943	130,802
Net Book Value	137,212	116,147
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Cost	904	202
Accumulated Amortization	228	$ 202
Net Book Value	$ 676

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets - Intangible Assets Acquired (Details) $ in Millions	9 Months Ended
	Jun. 30, 2023 USD ($)
B Medical Systems S.a.r.l and Subsidiaries
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 147.5

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 12.2	$ 7.6	$ 23.4	$ 36.1

Goodwill and Intangible Asset_8

Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023	$ 11,366
2024	50,664
2025	49,292
2026	45,908
2027	37,706
2028	31,219
Thereafter	85,900
Net Book Value	$ 312,055	$ 178,401

Warranty and Retrofit Costs (De

Warranty and Retrofit Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning Balance	$ 5,380	$ 2,491	$ 2,890	$ 2,330
Adjustments for acquisitions			2,303
Accruals	2,407	663	3,936	1,875
Costs incurred	(1,529)	(630)	(2,871)	(1,681)
Ending Balance	$ 6,258	$ 2,524	$ 6,258	$ 2,524

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Restructuring accrual	$ 0.8	$ 0.5	$ 0.3

Leases - Lease Expense (Details

Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lease, Cost [Abstract]
Operating lease costs	$ 3,332	$ 2,468	$ 9,450	$ 7,028
Amortization of assets	183	18	409	147
Interest on lease liabilities	12		26	5
Total finance lease costs	195	18	435	152
Total operating and finance lease costs	3,527	2,486	9,885	7,180
Variable lease cost	752	783	2,764	2,056
Short-term lease costs	415	640	1,009	1,357
Sublease income	(2)		(6)
Total lease costs	$ 4,692	$ 3,909	$ 13,652	$ 10,593

Leases - Assets and Liabilities

Leases - Assets and Liabilities - Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Assets and Liabilities, Lessee [Abstract]
Operating lease right-of-use assets	$ 67,352	$ 54,059
Operating Lease, Right-of-Use Asset, Statement of Financial Position	Other assets	Other assets
Accrued expenses and other current liabilities	$ 8,675	$ 6,924
Operating Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Long-term operating lease liabilities	$ 61,799	$ 49,227
Total lease liability balance	$ 70,474	$ 56,151

Leases - Assets and Liabiliti_2

Leases - Assets and Liabilities - Finance Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]
Property, plant and equipment, at cost	$ 4,511	$ 2,476
Accumulated amortization	(2,501)	(2,276)
Property, plant and equipment, net	$ 2,010	$ 200
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease Liability [Abstract]
Accrued expenses and other current liabilities	$ 673	$ 96
Finance Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Other long-term liabilities	$ 1,467	$ 98
Finance Lease, Liability, Noncurrent, Statement of Financial Position	Other long-term liabilities	Other long-term liabilities
Total finance lease liabilities	$ 2,140	$ 194
Finance Lease, Liability, Statement of Financial Position	Other long-term liabilities, Accrued expenses and other current liabilities	Other long-term liabilities, Accrued expenses and other current liabilities

Leases - Additional Information

Leases - Additional Information (Details)	Jun. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Weighted average remaining lease term, operating leases	11 years 2 months 19 days	10 years 9 months 25 days
Weighted average remaining lease term, finance leases	3 years 6 months 14 days	2 years 2 months 8 days
Weighted average discount rate, operating leases (as a percent)	4.21%	3.93%
Weighted average discount rate, finance leases (as a percent)	2.50%	1.29%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 2,947	$ 2,116	$ 7,895	$ 5,715
Operating cash flows from finance leases	12		26	4
Financing cash flows from finance leases	$ 169	$ 43	$ 377	$ 360

Leases - Assets Obtained in Exc

Leases - Assets Obtained in Exchange for Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lessee Disclosure [Abstract]
ROU assets obtained in exchange for lease liabilities, operating leases, net	$ 6,585	$ 122	$ 13,021	$ 7,612
ROU assets obtained in exchange for lease liabilities, finance leases	$ 576		$ 1,672

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Lease Payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Finance Lease, Liability, to be Paid [Abstract]
2023	$ 190
2024	711
2025	619
2026	453
2027	217
2028	38
Thereafter	9
Total future lease payments	$ 2,237

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Finance Lease, Liability, to be Paid, Gross Difference [Abstract]
Total future lease payments	$ 2,237
Less imputed interest	(97)
Total finance lease liabilities	$ 2,140	$ 194

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Lease Payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023	$ 2,937
2024	11,107
2025	10,797
2026	8,311
2027	7,875
2028	7,548
Thereafter	42,672
Total future lease payments	$ 91,247

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total future lease payments	$ 91,247
Less imputed interest	(20,773)
Total lease liability balance	$ 70,474	$ 56,151

Leases - Leases Not Commenced (

Leases - Leases Not Commenced (Details) $ in Millions	Jun. 30, 2023 USD ($)
Leases [Abstract]
Future lease payments	$ 9.3

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) shares in Millions			3 Months Ended	9 Months Ended
	Apr. 05, 2023	Nov. 28, 2022	Jun. 30, 2023	Jun. 30, 2023	Apr. 30, 2023	Nov. 04, 2022	Sep. 29, 2015
Equity, Class of Treasury Stock [Line Items]
Payments for repurchase of common stock				$ 672,116,000
Exercise tax related to share repurchases			$ 3,300,000	3,300,000
Share Repurchase Program, September 2015
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount						$ 0	$ 50,000,000
Share Repurchase Program, November 2022
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount						1,500,000,000
Stock repurchase program, remaining authorized repurchase amount			1,000,000,000	$ 1,000,000,000
Share Repurchase Program, November 2022, Accelerated Share Repurchase Agreement
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount						$ 500,000,000
Payments for repurchase of common stock		$ 500,000,000
Accelerated share repurchase (in shares)	4	6.1
Stock repurchase program, percentage of common stock expected to be repurchased under program (as a percent)		70%
Share Repurchase Program, April 2023
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					$ 500,000,000
Payments for repurchase of common stock			$ 172,100,000
Accelerated share repurchase (in shares)			4

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregated By Reporting Unit (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 165,948	$ 132,735	$ 492,715	$ 417,931
Life Sciences Products, excluding B Medical
Disaggregation of Revenue [Line Items]
Total revenue	$ 47,810	$ 47,369	$ 139,386	$ 150,861
Reporting unit, name of segment	Life Sciences Products	Life Sciences Products	Life Sciences Products	Life Sciences Products
B Medical
Disaggregation of Revenue [Line Items]
Total revenue	$ 26,761		$ 83,705
Reporting unit, name of segment	Life Sciences Products	Life Sciences Products	Life Sciences Products	Life Sciences Products
Sample Repository Solutions
Disaggregation of Revenue [Line Items]
Total revenue	$ 27,531	$ 26,000	$ 82,452	$ 78,806
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services	Life Sciences Services	Life Sciences Services
Genomic Services
Disaggregation of Revenue [Line Items]
Total revenue	$ 63,846	$ 59,366	$ 187,172	$ 188,264
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services	Life Sciences Services	Life Sciences Services

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Millions	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2022
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Contract assets	$ 20.3		$ 18.2
Contract with Customer, Liability [Abstract]
Contract liabilities	45.2		$ 39.7
Revenue recognized	$ 26.8	$ 13.4

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Remaining Performance Obligations (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 87,432
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 62,778
Unsatisfied performance obligation, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 24,654
Unsatisfied performance obligation, period

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Costs to Obtain and Fulfill a Contract (Details)	Jun. 30, 2023
Capitalized Contract Cost [Abstract]
Sales commission amortization period	60 months

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 3,995	$ 3,485	$ 10,091	$ 20,033
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	3,604	3,178	8,997	18,433
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 391	$ 307	$ 1,094	$ 1,600

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Granted (Details) - shares	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	590,066	231,696
Restricted Stock, Time Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	311,609	94,429
Board of Director Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)		49,063
Restricted Stock, Performance Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	278,457	88,204

Stock-Based Compensation - Time

Stock-Based Compensation - Time-Based Restricted Stock Unit Grants (Details) - Restricted Stock, Time Based Shares	9 Months Ended
	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Award vesting percentage (as a percent)	33.33%

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance-Based Restricted Stock Unit Grants (Details)	9 Months Ended	12 Months Ended
	Jun. 30, 2023	Sep. 30, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Performance-based awards granted, percentage (as a percent)	100%	100%
Performance-based awards granted, percentage, maximum threshold met (as a percent)	200%	200%
Performance goal measurement period (in years)	3 years

Stock-Based Compensation - Re_2

Stock-Based Compensation - Restricted Stock Unit Activity - Tabular Disclosure (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Shares
Outstanding at beginning of period (in shares)			538,238
Restricted stocks granted (in shares)			590,066	231,696
Vested (in shares)			(263,777)
Forfeited (in shares)			(104,220)
Outstanding at end of period (in shares)	760,307		760,307
Weighted Average Grant-Date Fair Value
Outstanding at beginning of period (in dollars per share)			$ 71.99
Granted (in dollars per share)	$ 42.35	$ 80.58	55.10	$ 103
Vested (in dollars per share)			55.76
Forfeited (in dollars per share)			73.62
Outstanding at end of period (in dollars per share)	$ 66.22		$ 66.22

Stock-Based Compensation - Re_3

Stock-Based Compensation - Restricted Stock Unit Activity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Withholding tax payments on net share settlements on equity awards			$ 4,924
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Withholding taxes remitted	$ 100	$ 100
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)	$ 42.35	$ 80.58	$ 55.10	$ 103
Fair value of restricted stock awards vested	$ 100	$ 200
Withholding taxes remitted			$ 4,900	$ 25,100
Withholding tax payments on net share settlements on equity awards			$ 4,900	$ 0

Stock-Based Compensation - Re_4

Stock-Based Compensation - Restricted Stock Unit Activity - Unrecognized Compensation Cost (Details) - Restricted Stock Units (RSUs) $ in Millions	9 Months Ended
	Jun. 30, 2023 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 27.4
Unrecognized compensation cost, estimated weighted average amortization period	1 year 10 months 24 days

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - shares	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued under employee stock purchase plan (in shares)	39,479	51,133
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock (as a percent)	85%

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	$ 559,914			$ 1,263,784
Derivative Asset, Statement of Financial Position	Prepaid expenses and other current assets			Prepaid expenses and other current assets
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration liability	$ 0	$ 1,400	$ 18,500
Fair Value, Recurring
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	559,914			$ 1,263,782
Foreign exchange contracts				634
Net investment hedge	984			124,789
Total Assets	1,150,224			1,764,009
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange contracts	428			230
Total Liabilities	428			230
Fair Value, Recurring | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	589,326			374,804
Fair Value, Recurring | Fair Value, Inputs, Level 1
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	127,592			651,800
Total Assets	716,918			1,025,855
Fair Value, Recurring | Fair Value, Inputs, Level 1 | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	589,326			374,055
Fair Value, Recurring | Fair Value, Inputs, Level 2
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	432,322			611,982
Foreign exchange contracts				634
Net investment hedge	984			124,789
Total Assets	433,306			738,154
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange contracts	428			230
Total Liabilities	$ 428			230
Fair Value, Recurring | Fair Value, Inputs, Level 2 | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents				$ 749

Fair Value Measurements - Conti

Fair Value Measurements - Contingent Consideration Liability (Details) - USD ($) $ in Millions	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Business Combination, Contingent Consideration, Liability [Abstract]
Contingent consideration liability	$ 0	$ 1.4	$ 18.5

Income Taxes - Provision (Benef

Income Taxes - Provision (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense (benefit)	$ (1,207)	$ 7,293	$ (9,107)	$ (560)
Deferred tax benefit resulting from the extension of a tax incentive in China			1,400
Benefit related to stock compensation windfalls				4,600
Charge to increase the deferred tax liability to reflect a change in the blended state income tax rate that results from the sale of the semiconductor business assets				$ 700
Pre-tax income not subject to income taxes	$ 18,500		$ 18,500

Income Taxes - Examination (Det

Income Taxes - Examination (Details)	9 Months Ended
	Jun. 30, 2023
Earliest Tax Year
Income Tax Contingency [Line Items]
Year subject to examination	2017

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	Jun. 30, 2023 USD ($)
Income Tax Disclosure [Abstract]
Anticipated unrecognized tax benefit reduction during next twelve months	$ 1.6

Net (Loss) Income per Share - T

Net (Loss) Income per Share - Tabular Disclosure (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Loss from continuing operations	$ (2,463)	$ (7,015)	$ (15,689)	$ (5,973)
Income (loss) from discontinued operations, net of tax	993	(2,555)	(1,943)	2,159,597
Net (loss) income - basic	(1,470)	(9,570)	(17,632)	2,153,624
Net (loss) income - diluted	$ (1,470)	$ (9,570)	$ (17,632)	$ 2,153,624
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted average common shares outstanding used in computing basic (loss) income per share (in shares)	63,432	74,989	68,494	74,879
Weighted average common shares outstanding used in computing diluted (loss) income per share (in shares)	63,432	74,989	68,494	74,879
Earnings Per Share, Basic [Abstract]
Loss from continuing operations (in dollars per share)	$ (0.04)	$ (0.09)	$ (0.23)	$ (0.08)
Income (loss) from discontinued operations, net of tax in Basic (in dollars per share)	0.02	(0.03)	(0.03)	28.84
Basic Net (loss) income per share (in dollars per share)	(0.02)	(0.13)	(0.26)	28.76
Earnings Per Share, Diluted [Abstract]
Income (loss) from continuing operations in diluted (in dollars per share)	(0.04)	(0.09)	(0.23)	(0.08)
Income (loss) from discontinued operations, net of tax in diluted (in dollars per share)	0.02	(0.03)	(0.03)	28.84
Diluted Net (loss) income per share (in dollars per share)	$ (0.02)	$ (0.13)	$ (0.26)	$ 28.76

Net (Loss) Income per Share - A

Net (Loss) Income per Share - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted earnings per share (in shares)	334,467	59,513

Segment and Geographic Inform_3

Segment and Geographic Information - General Information (Details) - segment	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2	2	2
Number of operating segments	2	2	2	2
Number of reportable segments, previously operated	3	3	3	3

Segment and Geographic Inform_4

Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Total revenue	$ 165,948	$ 132,735	$ 492,715	$ 417,931
Amortization of other intangible assets	12,200	7,600	23,400	36,100
Purchase accounting impact on inventory	2,956		8,737
Restructuring charges	812	25	3,773	319
Contingent consideration - fair value adjustments	(1,404)		(18,549)	600
Tariff adjustment				(486)
Total operating (loss) income	(15,836)	(5,073)	(56,498)	(10,106)
Interest income	11,347	6,822	32,406	9,933
Interest expense		(2,101)		(4,111)
Loss on extinguishment of debt				(632)
Other, net	819	630	(704)	(1,617)
(Loss) income before income taxes	(3,670)	278	(24,796)	(6,533)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	4,656	1,810	13,725	5,424
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	7,522	5,745	22,403	18,064
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	74,571	47,369	223,091	150,861
Total operating (loss) income	(4,878)	1,965	(25,077)	11,173
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	91,377	85,366	269,624	267,070
Total operating (loss) income	(3,813)	697	(13,302)	10,759
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	165,948	132,735	492,715	417,931
Total operating (loss) income	(8,691)	2,662	(38,379)	21,932
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense	$ (7,397)	$ 155	$ (11,970)	$ 8,717

Segment and Geographic Inform_5

Segment and Geographic Information - Financial Information for Business Segments - Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Total assets	$ 3,069,416	$ 3,716,122
Operating Segments
Segment Reporting Information [Line Items]
Total assets	1,772,719	1,228,393
Operating Segments | Life Sciences Products
Segment Reporting Information [Line Items]
Total assets	948,701	378,790
Operating Segments | Life Sciences Services
Segment Reporting Information [Line Items]
Total assets	$ 824,018	$ 849,603

Segment and Geographic Inform_6

Segment and Geographic Information - Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Cash and cash equivalents, restricted cash, and marketable securities	$ 1,296,074	$ 2,305,081
Deferred tax asset	599	1,169
Other assets	623	181,479
Assets	3,069,416	3,716,122
Operating Segments
Segment Reporting Information [Line Items]
Assets	$ 1,772,719	$ 1,228,393

Segment and Geographic Inform_7

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Tabular Disclosure (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 165,948	$ 132,735	$ 492,715	$ 417,931
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	91,018	88,380	267,437	272,750
Rest of Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	23,594	17,148	84,448	57,177
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	8,806	8,101	20,009	23,215
Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	19,064	86	44,901	1,305
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	12,766	12,906	38,153	39,704
Asia / Pacific / Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 10,700	$ 6,114	$ 37,767	$ 23,780

Segment and Geographic Inform_8

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Additional Information (Details) - country	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Concentration Risk [Line Items]
Number of countries	30		30
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk, North America [Member] | UNITED STATES
Concentration Risk [Line Items]
Concentration risk (as a percent)	99%	99%	99%	99%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Top Individual Customer | Minimum
Concentration Risk [Line Items]
Concentration risk (as a percent)	10%		10%

Commitments and Contingencies -

Commitments and Contingencies - Tariff Matter (Details) - Tariffs - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2021
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual		$ 6.1
Loss contingency payment	$ 5.9

Commitments and Contingencies_2

Commitments and Contingencies - Purchase Commitments (Details) $ in Millions	Jun. 30, 2023 USD ($)
Non-cancelable Commitments
Other Commitments [Line Items]
Other commitment	$ 70.8
Non-cancellable Contracts and Purchase Orders for Inventory
Other Commitments [Line Items]
Other commitment	48.1
Non-cancelable Information Technology-related Commitments
Other Commitments [Line Items]
Other commitment	$ 22.7

Commitments and Contingencies_3

Commitments and Contingencies - Contingencies (Details) - Edwards Vacuum LLC, Indemnification, Definitive Agreement, Third-party Warranty Claim - USD ($) $ in Millions	1 Months Ended		3 Months Ended
	Apr. 30, 2023	Jan. 31, 2023	Jun. 30, 2023	Mar. 31, 2023
Loss Contingency, Information about Litigation Matters [Abstract]
Loss contingency, damages sought, value		$ 1
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual				$ 2.5
Settled Litigation
Loss Contingency Accrual, Disclosures [Abstract]
Payment of Litigation Expense	$ 0.8		$ 0.8

Subsequent Event (Details)

Subsequent Event (Details) - Share Repurchase Program, March 2023 - USD ($) shares in Millions, $ in Millions	1 Months Ended
	Aug. 08, 2023	Mar. 31, 2023	Nov. 04, 2022
Subsequent Event [Line Items]
Stock repurchase program, authorized amount		$ 500	$ 1,500
Subsequent Event
Subsequent Event [Line Items]
Accelerated share repurchase (in shares)	2
Stock repurchased and retired during period	$ 91.6

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,470)	$ (9,570)	$ (17,632)	$ 2,153,624

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule10b51ArrModified [Flag]	false
NonRule10b51ArrModified [Flag]	false